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ABSTRACT

Purpose
Black/African-American women with breast cancer tend to have a worse prognosis for

survival compared to White women, the reasons for which are poorly understood.

Emerging research shows a higher frequency of HER-2 over-expression among
Black/African-American

(B/AA) women as compared to White women, suggesting its

potential role in the disproportionately poor prognosis of B/AA breast cancer patients.
Patients with HER-2 positive breast cancer tend to present with more aggressive tumors

and generally poor prognosis. HER-2 is estimated to be amplified or over-expressed in

20-40% of all breast cancers. Objectives of this study were to assess prevalence of

HER-2 testing, proportion of patients with positive status, and demographic predictors
of both testing and HER-2 tumor status among a sample of B/AA patients from
Connecticut.

Methods

A retrospective cross-sectional study was conducted to analyze data from the
Connecticut Tumor Registry (CTR), a population-based statewide registry which is part

of the National Cancer Institute Surveillance, Epidemiology and End Results (SEER)

program. Study cases included all B/AA breast cancer patients (n=644) diagnosed
between January

2000 and December 21 2003. HER-2 testing and tumor status were

obtained from pathology reports located in patient files at the CTR. Odds ratios (ORs)

and confidence intervals (CIs) were estimated using multivariate logistic regression
models. Prevalence of established and suspected prognostic factors was compared to
that of White cases as recorded in the SEER public use database.

Results
HER-2 testing was conducted for 477 (74.1%) of 644 cases. Actual status (positive or

negative) was available for 441, of which 20.6% (n=91) were HER-2 positive. Status
was unknown for the remaining patients (n=36), but there was indication in the

pathology report that the test had been ordered. Residence of B/AA women in Fairfield

County was positively associated with HER-2 test administration (OR=22.46, 95%CI
1.68-300.32, P=0.02) when compared to residence in Hartford County, where as the
likelihood of having a HER-2 test among residents of the other six counties was

equivalent to those living in Hartford. Compared to patients diagnosed in 2000, patients
diagnosed in 2003 were less likely to test positive for HER-2 (OR=0.35, 95% CI 0.130.97, P=0.04). Compared to White patients, B/AA tended to have larger and higher-

grade tumors, live in lower-income areas, were more frequently axillary lymph nodepositive and hormone-receptor negative, and showed higher prevalence of ductal

histology.
Conclusion
Residence in Fairfield County increased the likelihood of HER-2 testing, suggesting

potential disparity in disease management. The moderate rate of HER-2 positivity
observed among study cases suggests that HER-2 expression may not explain the

tendency for poor prognosis of B/AA breast cancer patients. Prevalence of HER-2
positivity was not constant across the four years of the study, though this might be a
spurious result. Comparison of study cases with SEER White cases shows a

disproportionately high presence of other adverse prognostic factors among study cases,
supporting the established racial disparity in survival.
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INTRODUCTION
Both nationally and within the state of Connecticut (CT),2 there is a wide disparity in

breast cancer survival between White and Black women. While breast cancer
incidence is notably higher among White women as compared to Black women,

prognosis is consistently worse for Black women. 2 According to the Surveillance,
Epidemiology, and End Results (SEER) database, the national age-adjusted breast
cancer incidence rates for the period 1998-2002 were 141.1 per 100,000 for White

women, and 119.4 per 100,000 for Black women. 2 Paradoxically, age-adjusted death
rates due to breast cancer based on the same period show the opposite trend, with a

mortality rate of 25.9 per 100,000 for White women, and 34.7 per 100,000 for Black
women. 2 Within CT, the disparity in survival persists. While annual incidence rates
are higher for CT White women (145.5/100,000 for the rate period 1998-2002) as

compared to Black women (116.7/100,000), the annual death rate due to breast cancer
for the rate period 1998-2002 was 26.2/100,000 for White women, and 31.5/100,000
for Black women. Within CT, African-American women are reportedly 1.7 times
more likely to die from breast cancer than are White women. 3

Extensive research has been conducted to identify demographic, socio-economic and

biologic factors that may predispose Black women to a poorer prognosis as compared
to White women. Significant differences in outcome between White and Black breast

cancer patients have been observed after consideration of age, 4 socio-economic status,
insurance

status,4 disease stage at diagnosis, nodal status and differential use of

systemic therapy. Poor prognosis among Black women extends beyond the United

States, with a pattern of early-onset disease characterized by high rates of aneuploidy
and hormone receptor negativity observed for breast cancer detected in several
western African nations. 4 Parallels in breast carcinoma characteristics between

African-American and western continental African women suggest the influence of

founder mutations in breast carcinoma susceptibility genes or in genes related to
hormone metabolism. 4 Within the United States, African-American breast cancer

patients are more likely to present with a later disease stage, larger tumor size, and
more lymph node nvolvemenv as compared to White women. Tumors of Black
women are reportedly higher grade and more frequently negative for estrogen

receptors (ER) and progesterone receptors (PR). 5 Research has demonstrated that
several of these biologic factors including recurrence, 6’7’8 large tumor size, 6’8 ER-

negativity, 6’s and lymph node involvement, 6’9 are associated with positive HER-2
status, suggesting that the disparity in breast cancer outcome between Black and White

CT women may be related to differential rates of HER-2 expression.

Little is known about potential racial/ethnic differences in genetic alterations that may

be associated with recurrence and overall survival in breast cancer patients. 5 One such
marker of interest is the HER-2/neu oncogene. Over-expression of human epidermal

growth factor receptor-2 (HER-2/neu), also known as c-erbB-2, defines an aggressive

subtype of breast cancer that requires targeted treatment. 8 The effective treatment of
patients with breast cancer over-expressing HER-2/neu (hereafter referred to as HER-

2) requires their identification through systematic testing of the tumor. Currently, the
prevalence of HER-2 is unknown among either B/AA or White breast cancer patients.

The prevalence of testing within the groups is also unknown, and any estimates may

be confounded by disparities in reporting. A greater prevalence of HER-2 over-

expression among B/AA cases could help to explain the observed disparities in breast
cancer survival.

In addition to HER-2 over-expression, alterations shown to have a negative effect on
prognosis include those occurring in the tumor suppressor gene p53 and in the c-met
s
proto-oncogene. A 2004 study found that alterations in p53 were significantly more

common in African-American women as compared with White women, 5 providing

additional evidence that the breast cancer tumors diagnosed in African-American
women are generally more aggressive than those of White women. The study

confirmed earlier reports that African-American women were significantly more likely
to have later stage tumors, larger tumors, positive lymph nodes, and tumors with

higher histologic and nuclear grades. s The investigation supports a clear pattern of
higher risk for African-American women with respect to several prognostic indicators,

although results showed no significant racial/ethnic differences in either of the other
genetic alterations assayed, including HER-2. The prevalence of HER-2 positive
status among African American patients was observed to be 38.9%, as compared to

40.6% for White patients, a statistically insignificant difference. The lack of
difference is consistent with other studies that likewise had not observed racial
differences in frequency of HER-2-positive tumors. 5 However, the study reported

ambiguity concerning the clinical significance of intermediate staining (i.e., 2+) for
HER-2. Because the analysis designated only the highest staining category (3+) as

positive for HER-2, the possibility of an association between HER-2-positive tumors
and reported race/ethnicity may exist given a lower staining threshold for positive
status.

Association between race and HER-2 expression was studied in a recent investigation

of patients with uterine serous papillary carcinoma (USPC). Researchers found a

significantly higher rate of HER-2 expression among Black female patients as

compared to White female patients.

Of the patients evaluated, 70% of Black patients

showed strong (3+) expression, compared with 24% of White patients, an association
which persisted after stratifying by age. A significant inverse association between
survival and HER-2 expression indicated that HER-2 expression accounted for much

of the race disparity in survival in this patient population.

Overall results showed

that over-expression of HER-2 in USPC is an independent variable associated with

poor outcome, occurs more frequently in Black women and may contribute to racial
disparity in survival. The study identified HER-2 over-expression to be the only

independent variable correlated with survival, and appears to be the first report of a
racial difference in HER-2 status in a type of cancer. Previous reports of patients with
endometrial cancer had found correlations between p53 alterations and poor survival

rates, and a two-fold increase in frequency of p53 over-expression in Black patients as

compared to White.

However, among those with p53 over-expression, survival of

Black patients was still observed to be worse, suggesting that p53 was not the only
determinant of racial disparity in survival. Researchers speculate that observed

differences in likelihood of p53 over-expression between tumor specimens obtained

from African-American and White breast cancer patients, after consideration of stage
and age at diagnosis, suggest that race may be either a determinant or a surrogate for
other determinants of aggressive breast carcinoma and specific cell cycle defects that
contribute to survival outcome. 11

Prognosis among breast cancer patients in CT has been shown to vary not only by
racial category but by geographic location. An evaluation of geographic differences

in survival during the 1984-1995 period found survival to be significantly worse for
cases living within five urban areas around the State. In particular, the risk of death by

breast cancer in Waterbury was 1.47 times greater than that of cases diagnosed
elsewhere around CT, with secondary concentrations of higher than expected mortality
identified in Bridgeport, Hartford-East Hartford, New Haven, and New Britain. 3

Ongoing surveillance has been recommended to better determine the reasons for the
geographic patterns noted, as is research into the disparities among racial groups in
terms of mortality from breast cancer. 3 Assessing HER-2 testing practices among CT

breast cancer cases by reported racial category may identify testing patterns across
both geographic areas and population subgroups. A statewide assessment of HER-2
status testing is important as the testing is necessary to identify patients who are

eligible to receive targeted therapy. As breast cancer prognosis varies across both race
and geography, an evaluation of factors that predict testing may help to explain the

prognostic trend occurring in particular population groups.

Well-established evidence for HER-2 as an independent prognostic factor of
7
recurrence and survival justifies the use of systemic, targeted therapy. Over-

expression of HER-2 protein and/or amplification of the HER-2 gene occurs in

approximately 20-40% of primary invasive breast cancers. 6 Over-expression of HER-2
is considered to be an adverse prognostic factor associated with aggressive behavior in

the tumor; 2’3 specifically, faster rate of tumor growth, increased rate of metastasis,

poor prognosis, decreased disease-free survival, and decreased overall survival.
Extensive research has found association between over-expression of HER-2 and

poorly differentiated, high-grade tumors, high rates of cell proliferation, lymph node
involvement, and resistance to some chemotherapies. 8 Efforts to determine predictors

of local recurrence, an adverse prognostic factor for breast cancer and suspected

predictor of distant metastatis, 4 have found a higher proportion of HER-2 amplified
cases among early invasive breast cancer patients with local recurrence as compared

with non-recurrent patients. 7 A significant association has also been found between

HER-2 positivity and histological tumor grade in all patients, and with lymph node
involvement and tumor stage in recurrent patients. About half of HER-2-positive

breast cancers express the hormone receptors for estrogen, progesterone, or both, yet

levels in these tumors are usually lower than in HER-2-negative, hormone-receptor-

positive tumors. 8 The compilation of these factors contribute to the relative resistance
of HER-2-positive breast cancers to treatment with tamoxifen, and to increased risk of
recurrence among women with HER-2-positive breast cancer as compared to those

with HER-2-negative breast cancer. 8

The established poor prognosis associated with HER-2 over-expression/amplification

inspired the development of trastuzumab, an anti-cancer therapy targeted at the HER-2
cell surface receptor. The United States Food and Drug Administration (FDA)

approved trastuzumab in 1998 as a first-line treatment in combination with paclitaxil
for HER-2-positive cancers, 5 and the drug has since been shown to be active in

patients with HER-2-positive metastatic breast cancer. 7 By targeting tumor cells that

over-express HER-2 protein, trastuzumab has been shown to impact the survival of
HER-2-positive metastatic breast cancer patients 7 when administered either alone or
in combination with chemotherapy. 3 Trastuzumab’s ability to modify the natural

history of breast cancer is suggested by studies that found the treatment to increase
survival of patients when administered following or sequentially with chemotherapy in

early-stage breast cancer. 7
Following excision of early-stage breast cancer and completion of chemotherapy,
trastuzumab was found to reduce the rate of recurrence, particularly distant recurrence,

by almost 50% as compared to observation. 3 A related study found that concurrent
administration of trastuzumab with adjuvant chemotherapy significantly improves
survival outcomes among women with surgically-removed HER-2 positive breast

cancer. 5 Among HER-2 positive patients who continued treatment after doxombicin

and cyc!ophosphamide, the relative reduction in mortality rate associated with
trastuzumab was 39%. 15 Results of these trials show a benefit of trastuzumab at local
or regional and distant sites, 5 and the reported observations clearly indicate that

trastuzumab can improve outcomes among women with HER-2-positive breast
cancer. 8

The utility of HER-2-based therapy in the clinical management of invasive breast
cancer patients depends, of course, on HER-2 testing of tumors. Results from several
clinical studies indicate that the level of HER-2 over-expression correlates with degree

of clinical benefit due to trastuzumab; that patients with tumors having higher HER-2
receplor over-expression and/or amplification of the HER-2 gene benefit the most

from the treatment.
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A wide range of techniques have been used in research to determine HER-2 status.
Two technologies currently dominate the routine clinical pathology laboratory;
determination of HER-2 protein over-expression by immunohistochemistry (IHC) and

HER-2 gene/DNA amplification by fluorescence in-situ-hybridization (FISH). 7 The

FDA has approved two commercially available FISH assays (Path Vision HER-2
DNA probe kit [Vysis, Inc, Downers Grove, IL] and INFORM HER-2/neu Test
[Ventana, Inc, Tucson, AZ]), and one commercially available IHC kit (HercepTest

[DAKO, Inc., Glostrup, Denmark, and Carpinteria, CA]). While there is debate over
which test is superior for accurate analysis of HER-2 expression, any of the three

approved tests are reportedly reliable for making clinical decisions, depending on the

preference of the clinician. The accuracy of results achieved through these assays;
and hus the apparent prevalence of positive status among groups, may be influenced

by the assay antibody/probe, the methodology, and the experience of personnel. 6

In 2000, the College of American Pathologists (CAP) and the American Society of
Clinical Oncology (ASCO) issued several recommendations regarding the significance

of HER-2 testing in the diagnostic workup of breast cancer patients. 9 In spite of
extensive evidence supporting the value of HER-2 testing, the availability of the test
kits and recommendations from the CAP and ASCO, it is reported that institutional

policies to incorporate testing for the HER-2 tumor marker in the diagnostic work up
of breast cancer patients were not implemented until 2001 .9

To date, we know of only one investigation that assessed the prevalence of HER-2
testing in the clinical workup of cancer patients. A 2004 retrospective cross-sectional
analysis of 451 women with breast cancer found that frequency of HER testing
increased two-fold from 1999 to 2000. 9 Factors found to increase likelihood of HER-

2 testing were absence of estrogen receptors, physicians with specialty in surgery, and

having capitated insurance. 9 Likewise, research into risk factors for positive HER-2
status has produced limited findings.

The current study aims to determine the

prevalence of HER-2 testing and demographic predictors of HER-2 status among
B/AA breast cancer patients in CT. Data collection and analysis described below

comprises the first phase of a two-phase study. Phase I evaluated HER-2 data for
B/AA cases. Phase

II will evaluate the HER-2 information of White patients matched

on age and stage within each year.

METHODS
Study Population
All B/AA female patients diagnosed with breast cancer (ICD-O-3 C500-C509)

between January 1 2000 and December 31 2003 were identified within the

Connecticut Tumor Registry (CTR) database. Males were excluded because the vast

majority of prior studies were restricted to females. Patients diagnosed outside of CT
were also excluded. The initial sample contained 666 cases. Twenty-two cases were

subsequently excluded because the pathology report indicated white race, in contrast
to the CTR data file; or because the report study

ID was a duplicate number. A total of

644 cases comprised the final sample.

Data Collection
Identified cases were compiled into a print-out including patient ID number, date of

birth, diagnosis year, and a random ID number generated for each patient. The table
was used as a checklist to indicate patient ID numbers for pathology report selection.

A data abstraction form was used to collect the following information from each
patient’s pathology report: date of chart review, HER-2 status, HER-2 test method,
HER-2 test value, HER-2 test date, location of the laboratory used, and use of
tamoxifen (see Appendix 1). Most reports were housed in hard-copy format in the

CTR office, while some older reports were located in laser fiche. Dates of birth,
diagnosis year, female sex and Black race were verified prior to recording each case to
confirm that the patient described in the report matched the one listed on the patient ID

print-out.

Information was recorded as "unknown" if not explicitly stated in the pathology

report. When reports listed several dates associated with HER-2 testing, such as date
of collection, service, order or receipt, the earliest date was recorded. When multiple
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IHC tests or both IHC and FISH tests were performed, the earliest date of testing was
recorded. After error checks were performed to verify input accuracy, information
was entered into an SPSS data file which was saved daily on a CTR password-

protected computer. With the exception of dates and HER-2 test values, all variables
were re-coded to facilitate statistical analysis. Several new variables were created to
account for unexpected findings in pathology reports, such as conflicting race values,
test results presented with no status decision, multiple diagnosis years, and multiple

values of IHC and/or FISH test results.

Patients who had several diagnoses of breast cancer were identified and the year of

diagnosis was recorded. HER-2 test method was assumed to be IHC if results were

presented as 1 +,2+,3+ or 4+, or if "staining" or "HercepTest" was reported. Reports
containing conflicting or unknown race values were coded accordingly. Reports were
coded as having conflicting race values if Black race value as well as some other race
value were seen as describing the same patient. Seven patients were identified under
more than one ID number. Only one ID was chosen for each patient, with extra ID

numbers excluded.

If no specific HER-2 test value was listed, the HER-2 status recorded reflected the
overall decision stated in the pathology report, i.e. positive or negative. HER-2 test
values were: positive, negative, borderline, conflicting, value given only with no

decision, test ordered but not in chart, and unknown. When reports showed conflicting
test scores or status decisions, they were classified as conflicts (n=l 9). The following
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conflict types were observed: IHC negative/IHC positive, IHC borderline/FISH

negative, IHC negative/FISH borderline, IHC negative/IHC positive, IHC

positive/FISH negative, IHC positive/negative/FISH positive, IHC positive/IHC
negative, IHC positive/negative/FISH negative. When FISH value or status conflicted
with an IHC value, the FISH value was chosen to represent tumor status (n= 12).

Conflicting values were updated to include only IHC conflicts, with status for all cases
with FISH/IHC conflicts re-coded using the observed FISH test result and the

DakoCytomation Interpretation guide as a guide for amplification threshold.
Accordingly, all FISH results of > 2 were decidedly amplified. Of the 19 conflicts
recorded, seven reflect disagreement among IHC results. The remaining conflicts
include inconsistent IHC and FISH decisions. Of all conflict types, the most common

(n=8, 42%) is a positive IHC score with a negative FISH score. For reports showing a
test result but no pathology decision, a decision was made based on the score shown in

accordance with DAKO Herceptest guidelines, 22 as all were IHC test results. The

guideline considers an IHC score of >2+ to indicate HER-2 over-expression, with 0
and 1 + considered HER-2 negative. 22

Data were checked for errors by cross tabulating variables, and conflicts resolved by
consulting the original data source. The HER-2 data file was merged with the CTR
database on patient ID number. For confidentiality purposes, patient ID number was
then deleted from the merged file and the random ID number corresponding to each

patient was substituted. Accuracy was confirmed by matching the list of patient study

ID, diagnosis date, age, and HER-2 status from the merged file with information on

12

corresponding cases in the unmerged file. Variables in the CTR file were sequence
number of the tumor, demographic, biologic and treatment indicators (see Appendix

Study procedures for data collection and management were approved by the
Institutional Review Board of the University of Connecticut Health Center (#06-21 l-

2) and the Human Investigation Committee of the State of CT Department of Public
Health (#E-03).

Variable Definition

Diagnosis age was collapsed into five categories including age 25-39, 40-49, 50-59,
60-69, and 70+. The variable Medicare age was created and classified as: age <65,
and age > 65. Values levels for the CTR variables were maintained according to the

Surveillance, Epidemiology and End Results (SEER) Program Coding and Staging

Manual 2004, 4h edition. 23 SEER summary stage, a Collaborative Staging System that
accounts for tumor size, extension, lymph node status and metastatic

status,23 was

collapsed into categories representing in situ, local, regional and distant stages. ER and

PR status were condensed into test not done, negative, positive, and unknown.
Unknown included unknown value, uncertain value, or test ordered only. Tumor size
was classified according to prognostic categories indicated by the AJCC Cancer

Staging Manual, 6h edition "4, <2cm (T1), >2cm-5cm (T2), and >5cm (T3). Number of
positive lymph nodes was categorized as follows: 0, 1-4, 5+, and unknown.
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Histologic type was coded according to the International Classification of Diseases for

Oncology, 3 d edition (ICD-O-3). 25 Ductal histology (n=484) was assigned to patients
with a histologic type of 8500: Intraductal carcinoma, noninfiltrating, NOS, and

Infiltrating duct carcinoma, NOS; 8501: Comedocarcinoma, noninfiltrating, and
Comedocarcinoma, NOS; 8503: Intraductal papilloma, noninfiltrating intraductal

papillary adenocarcinoma, and intraductal papillary adenocarcinoma with invasion;
8510: Medullary carcinoma, NOS; 8513: Atypical medullary carcinoma; 8523:

Infiltrating duct mixed with other types of carcinoma. Lobular carcinoma (n-36) was
assigned to patients with a histologic type of 8520: Lobular carcinoma in situ, NOS,
and Lobular carcinoma, NOS; 8524: Infiltrating lobular mixed with other types of
carcinoma. Mixed ductal and lobular (n=48) was assigned to patients with a histologic

type of 8522: Intraductal carcinoma and lobular carcinoma in situ, and infiltrating duct
and lobular carcinoma. Other/unknown histologic type (n=76) comprises the

remaining types which existed beyond the range of ductal and lobular neoplasms

(n=65) or referred to unspecified inflammatory carcinoma (type 8530, n=7), or Paget
disease with intraductal/infiltrating carcinoma of the breast (types 8541 and 8543,

n=4).

The dichotomous variable Nodal Status was defined as: no nodes positive, one or
more nodes positive. Tumor grades III and IV were combined into "high

grade"category.

2g

Using values for ER status, PR status, grade and positive lymph

nodes, variables were created to indicate whether or not each characteristic had been
tested. Each factor was considered to be tested if a value was given, or if it was

14

reported to be "documented but unspecified". The characteristics were considered not
tested when "unknown" was reported. Because testing of ER and PR status on biopsy

specimens of breast carcinoma prior to treatment is standard practice in breast cancer
management, 26 their indication in the patient profile may imply patterns of patient
treatment, and may predict HER-2 testing. To increase the number of cases within

categories, values within treatment variables representing primary surgery,

chemotherapy, radiation and hormone therapy were collapsed to indicate any
treatment, no treatment, or unknown for each respective type.

Variables were created to describe Counties in terms of population size, income, and

percent B/AA. Information for population size and racial composition was obtained
from he U.S. Census Bureau American FactFinder. 27 Population counts and

proportion B/AA, County composition, were expressed as continuous variables, with

Counly composition also dichotomized using the State proportion B/AA as the.cut
point. The variable County income was created based on the 1999 median household
income for each County in dollars, and was represented in continuous form and
relative to the State median household income. County and State income data was

taken from the U.S. Census Bureau

8

Five counties contained fewer than 30 cases

and were combined into one category, Combined, to facilitate analysis. The combined

category includes: Litchfield, Tolland, Windham, New London, and Middlesex.

The HER-2 status variable used for both descriptive and regression analyses was a

collapsed version of the HER-2 status data collected from pathology reports. HER-2
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status of the tumor is categorized as follows; Positive status (n=91) includes all reports

of positive by either IHC or FISH (n=90), and a FISH-positive but IHC-negative

(n=l). Negative status (n=350) includes all reports of negative (n=328), FISH-negative
or borderline but IHC-positive (n= 11), reports of borderline (n=7), and all test scores

given without status decisions (n=4; all IHC-negative study decisions). Unknown
status (n= 203) includes conflicting IHC information (n=7), test ordered only but no

value given (n=29), and no indication of HER-2 testing (n= 167).

To assess whether or not a HER-2 test was administered, the variable HER-2 Status
was collapsed into HER-2 Tested (1 = HER-2 mentioned in the pathology report, and

0= test not mentioned). Unknown values for all variables were set to missing for
correlation and regression analyses.

Selected patient characteristics were analyzed from the SEER database for patients of
White and Black race and otherwise meeting inclusion criteria. Using SEERStat

software version 6.2.3,29 cases were selected based on the following specifications:

Race value of White or Black, Connecticut 1973+ SEER Registry, Primary site code
of 500-509, female sex, malignant behavior, and 2000-2003 diagnosis years. Variable

values were labeled and collapsed according to SEER 2004 coding manual

guidelines, 2 and consistently with study variables. Denominators used for
proportions were total cases of each race meeting selection criteria; 10,199 White

patients and 651 Black patients. 29
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Statistical Analysis
Associations of patient characteristics in relation to HER-2 testing and HER-2 status

were examined using the t-test of independent samples to compare means, and Pearson

chi-squared tests to compare proportions.

Regression models were built in a stepwise sequence. First, bivariate correlations
were evaluated using Spearman’s rho statistic for nonparametric data. The

Spearman

rho coefficient (r) indicates agreement, with an r value of one indicating complete

agreement, a value close to zero indicating little agreement, and negative values

indicating inverse correlations. If two similar variables, such as ER and PR, showed
high and significant correlation, only one was chosen for entry into regression models
to avoid collinearity. The following variables were tested for correlation: HER-2

tested, HER-2 status, diagnosis age, diagnosis year, ER testing, PR testing, grade

testing, nodal testing, tumor size, number of positive lymph nodes, nodal status,

County population size, County composition, binary County composition, County
income, binary County income, grade, ER status, PR status, histologic type and SEER

summary stage. Potential multi-collinearity was prevented by including in final
models only variables with coefficient values of <0.70. Correlations were considered

statistically significant at the 0.05 level (two tailed).

Univariate analysis

Univariate logistic regression analyses were performed to assess the association of key

demographic factors and likelihood of a patient’s tumor being tested for HER-2 status.
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Likewise, demographic and clinicopathologic factors were assessed for association
with HER-2 status of tumors. For univariate analyses, a P-value of 0.05 was chosen

as the entry criterion and 0. l0 as the removal criterion. Categorical variables were set
to indicator contrast with the first category as reference with the exception of

Medicare age, for which the last category was set to reference.

Variables examined for their association with HER-2 testing include: diagnosis age

(continuous) diagnosis year (2000, 2001, 2002, 2003), tumor size (continuous),
number of positive lymph nodes (continuous), nodal status (negative, positive),

County population size (continuous), County (Hartford, Fairfield, New Haven,
Combined), tumor grade (continuous), County composition (percent B/AA), County

composition in relation to CT composition (percent B/AA <_CT percent, >CT percent),

ER test done (not done/unknown, tested), ER status (negative, positive), histologic
type (ductal and related, lobular, mixed ductal and lobular), SEER summary stage

(local, regional, distant), County median household income in 1999 (countinous),

County median income in relation to CT median income (county income <CT, county
income > CT), PR test done (not done/unknown, tested), PR status (negative,

positive), nodal testing (not done/unknown, known), grade testing (unknown, known),
and Medicare age (>65, < 65). Consistent variable coding was used in subsequent
multivariate analyses.

The same variables were examined for their association with HER-2 status of the
tumor with the exception of ER test done,

PR test done, nodal testing and grade
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testing, because temporality could not be determined from the pathology reports. In
addition, whether or not standard tests were performed can be considered more of a
reflection of quality of care than related to the biological HER-2 status of the tumor.
Variables found to be associated with HER-2 testing or status at the P<0.10

significance level in univariate tests were eligible for inclusion in multivariate models.

Multivariate analysis

HER-2 testing
The following variables were assessed using a forward stepwise multivariate model in
relation to HER-2 testing; diagnosis age, diagnosis year, tumor size, grade, County,

County composition, histologic type, binary County income, ER test done, nodal
testing, grade testing, ER status, and nodal status. The same variables were entered
into the model to predict HER-2 status with the exception of ER, PR, grade, or lymph

node involvement testing. SEER summary stage was excluded from analyses due to its

high correlation with nodal status (r=-0.973). A forward (likelihood ratio) stepwise
strategy was employed for variable selection, with significance of 0.05 as the entry
criteria and 0.10 as the removal criteria. Variables found to be associated with HER-2
outcome at the P<0.05 significance level were included in the final analysis.

In addition to significance testing, variables of interest were selected for analysis
models based on clinical importance and exploratory interest. Also, statistical

problems with collinearity were considered in the selection of variables. Due to its
high correlation with number of positive lymph nodes (r- 0.940), SEER summary
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stage was not included in multivariate models. Other correlations observed to be high
and significant included County median income with County population size (r =

0.883), County median income relative to CT median income with County
composition (r = -0.764), ER status with PR status (r 0.786), and PR test done with

ER test done (r = 0.982). Because of high correlation between ER and PR variables,
separate sets of multivariate models predicting HER-2 testing and status were created
to include either ER test done and ER status or the analogous

PR variables. Main

models included ER values, which are more commonly referred to in the relevant
literature. Sensitivity analysis with PR variables is justified by the significant results

of univariate logistic analyses and high bivariate correlation with ER variables. The

binary County income measure rather than the continuous one was chosen to represent
income. County category was chosen to represent County due to a case count of <30

in five of the counties. All other County variables were excluded due to high
correlation or lack of importance. The Hosmer and Lemeshow goodness of fit test
was performed to assess model fit.

Ten clinical and demographic covariate variables known or suspected to affect
outcome, shown to be significant in univariate or forward stepwise analyses, or

relevant to the goals of the study were entered into a multivariate model predicting

HER-2 testing. Variables included in the final model predicting HER-2 testing were

diagnosis year (2000, 2001, 2002, 2003), diagnosis age (continuous), ER status

(negative, positive), ER tested not tested/unknown, tested), County of residence

(Hartford, Fairfield, New Haven, Combined), County median income (income < CT,
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income > CT), nodal status (negative, positive), tumor size (continuous), nodal testing

(not done/unknown, examined), and grade testing (unknown, known). Each chosen
covariate was chosen based on its significance in univariate or forward stepwise

models, with the exception of nodal status and tumor size which were evaluated for

exploratory interest.

HER-2 Status
The multivariate model predicting HER-2 status contained the following variables"

grade (continuous), nodal status (negative, positive), ER status (negative, positive),
diagnosis age (continuous), tumor size (continuous), histologic type (ductal and
related, lobular, mixed ductal and |obular), diagnosis year (2000, 2001, 2002, 2003)
and County of residence (Hartford, Fairfield, New Haven, Combined). Nodal status,

ER status and diagnosis year were shown to be significant in univariate analyses.
Review of scientific literature supported testing tumor grade, tumor size, stage, and

diagnosis age, although stage was excluded for its high correlation with nodal status.

County was included for exploratory interest.

Sensitivity analyses
The following sensitivity analyses were performed: replacement of diagnosis age with
Medicare age (>65 years versus <65 years), and exclusion of patients with distant

stage disease. These were performed to determine the influence of Medicare on
likelihood of testing, and to investigate if more advanced disease was associated with

higher or lower likelihood of testing.
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Regression results are expressed as odds ratios (ORs) with 95% confidence intervals

(CIs). P values reflect the 13 coefficient in the logistic model, and statistical
significance was accepted at P<0.05. All analyses were performed using Statistical

Package for the Social Sciences software (SPSS, Chicago, IL, USA), version 12.0.

RESULTS
Clinicopathologic and demographic characteristics of study participants are given in
Table 1. Of 644 eligible cases, the mean age was 57.68 years. The overwhelming

majority (93%) of patients live in one of three counties; Hartford (33.1%), Fairfield

(30.1%) and New Haven (29.8%). The tumors of most patients were tested for ER
status (84.3%) and PR status (84.5%). HER-2 characteristics of patients are given in

Table 2. The prevalence of known HER-2 testing among patients was 74% (477/644).
The type of HER-2 test most frequently reported was IHC (48.6%), followed by

unknown test type (47.5%), with only 2 reports (0.3%) of FISH testing exclusively.
The prevalence of HER-2 positive status among all tested cases was 19% (91/477),
and 21% among cases classified as being positive or negative (n=441).

Comparison with White Breast Cancer Patients

Clinicopathologic characteristics of study cases and a sample of white breast cancer
palients are listed in Table 3. As compared to White patients, B/AA patients in our

sample were younger at diagnosis, with 33% of study cases versus 22% of White
patients being younger than age 50. The majority of study patients (33%) lived in
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Hartford County, while the majority of White patients lived in Fairfield County (26%).

Approximately the same frequency of ER testing, PR testing, lymph node testing and
grade testing was reported for both groups. A larger proportion of White cases (56%)
had a tumor size of less than 2cm as compared to study cases (45%), while more study
cases had a tumor size between 2 and 5cm (35%) as compared to White patients

(28%). More study cases had a ductal histology (75%) as compared to White cases

(69%). The majority of both study patients (59%) and White patients (64%) had local
stage disease. A slightly higher proportion of study patients (31%) was node-positive
as compared to White patients (26.5%). More study patients had a grade III/IV tumor

compared to whites (47% versus 35% respectively). Study patients were more
frequently ER negative (33%) as compared to White patients (17%), and were more
often PR negative than White patients; 38% versus 27%, respectively. Fewer study

patients were alive at last follow up (82%) as compared to White patients (90%). The

groups .did not differ appreciably by diagnosis year, number of positive lymph nodes,
surgery, radiation therapy or laterality.

Testing for HER-2 Status
Table 4 displays demographic and clinical characteristics according to HER-2 testing.
Prevalence of reported HER-2 testing differed significantly by County (P=0.03), ER

testing (P<0.001), PR testing (P<0.001), nodal testing (P<0.001), grade testing

(P<0.001), tumor size (P<0.001), SEER summary stage (P=0.01), number of positive

lymph nodes (P<0.001), nodal status (P<0.001), tumor grade (P=0.001), ER status

(P<0.001), PR status (P<0.001), and treatment with chemotherapy (P=0.03). Of all
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Counties, the highest frequency of testing (n=37, 82.2%) appears to be in the

Combined category comprising Tolland, Windham, New London, Middlesex and
Litchfield. However due to the number of patients not tested in this category (n=8), the

County with the next highest testing frequency, Fairfield (n=151, 77.8%) should be
noted. The lowest frequency of testing is seen in New Haven County (n=128, 66.7%).

Frequency of HER-2 testing was highest among patients who show report of routine
tests such as ER testing (83.6%),

PR testing (83.8%), examination of lymph nodes

(78.1%), and evaluation of grade (76.3%), as compared to those who did not

reportedly receive these procedures. HER-2 testing was reported more frequently for
recipients of chemotherapy (79.4%) as compared to non-recipients (70.2%).

There was a higher rate of testing among patients with regional disease (79.1%)

compared to patients with local (73.4%) or distant (63.3%) stage disease. Testing was
more common among patients with ER-negative tumors versus ER-positive tumors

(88.5% versus 82.4%, respectively, P<0.001). The trend is similar for PR status, with
more testing among PR-negative patients as compared to PR-positive patients.

Although statistically significant, differences in test frequency by other clinical
characteristics were not substantial. Patients with a tumor size between 2 and 5cm had

the highest frequency of testing (n=186, 82.7%), with approximately 10% less

frequency of testing among those with smaller or larger tumors. Testing appears to be
evenly distributed regardless of nodal status or number of positive lymph nodes.
Differences in testing by grade were unappreciable.

24

The mean diagnosis age of tested patients is 57.08 years, and 59.37 years for patients
with unknown testing. When patients are divided by age group, testing is more

prevalent in the youngest age group, women aged 25-29 (81%, 47/58), while the
lowest frequency (68.9%, 47/151) appears in the oldest group of patients, age 70 and
over. Differences in HER-2 testing by age group were not significant. A statistically

insignificant yet interesting trend exists in testing prevalence by diagnosis year. There

appears to be a discontinuous upward trend in HER-2 testing according to diagnosis
year, with reported testing increasing from 69.2% (110/159) in 2001 to 78.3%

(126/161) in 2003. The rate of testing in 2000, 75.3% (110/146), is inconsistent with
the trend.

Time Trends

Table 5 displays the trend in testing of HER-2 and steroid receptor status by year. The

prevalence of HER-2 testing decreased from 75% in 2000 to 69% in 2001, then
increased steadily to 78% in 2003. The prevalence of ER testing is higher overall,

ranging from a high of 87% in 2000 to a low of 81% in 2001. Trend in PR testing is
almost identical to that in ER testing, ranging from 87% in 2000 to 82% in 2001. All
three tests show a decrease in prevalence during 200 l, although ER and PR remain

relatively stable in later years with HER-2 testing increasing in frequency during 2002
and 2003. Differences in test rates by year were not statistically significant.

Geographic Trends
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Trend in HER-2 and steroid-receptor testing by County is given in Table 6. Frequency

of HER-2, ER and PR testing appears to be highest in the Combined County category

comprising Tolland, Litchfield, Windham, Middlesex and New London. Frequency of
HER-2 testing is lowest (67%) in New Haven County, and increases to 76% in

Hartford, 78% in Fairfield and to 82% in the combination category (P=0.03). Both

ER and PR testing frequency are lowest (81%) in Fairfield County and highest (96%)
in the Combined County.

Demographic Trends
Table 7 displays frequency of HER-2 testing by County characteristics. Counties in
which the percentage of African-Americans is at or below the State percentage show a

higher frequency of testing (82.2%) as compared to counties above the state
percentage (73.5%). County income also appears to impact test prevalence, with
HER-2 testing more frequent (77.1%) in counties that have a median household
income greater than or equal to that of the State-wide median income as compared to

those with an income below that of the State (72.6%). Differences in testing by

County composition and income were not statistically significant.

HER-2 Status
Characteristics of study cases according to HER-2 status are given in Table 8. Of

patients for whom status was listed in the pathology report (i.e. positive, negative or
borderline), the percentage of positive status was 20.6% (91/441). HER-2 status
differed significantly by County (containing Hartford, Fairfield, New Haven and other,
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P=0.01), tumor size (P<0.001), number of positive lymph nodes (P<0.001), nodal
status (P<0.001), grade (P=0.01),

ER status (P<0.001) and PR status (P<0.001).

When considering all patients (n=644), Fairfield County (n=194) showed the highest
rate of positive status (36/194,

18.6%), with New Haven (n=192) showing the lowest

rate (21/192, 10.9%). New Haven shows the highest rate of unknown status (79/192,

41.1%), with the lowest rate of unknown status being in the combination category
(9/45, 20.0%). Patients with a tumor size between two and 5 centimeters showed the
highest rate of positive status (39/225, 17.3%) as compared to 12.1% (35/289) and
13.1% (8/61) for patients with smaller or larger tumors, respectively. Positive HER-2
status is more prevalent among those with positive nodal status (36/199, 18.1%) as

compared to negative (38/312, 12.2%)or unknown nodal status (17/133, 12.8%).
Positive HER-2 status is more prevalent among those with grade III/IV tumors

(53/304, 17.4%) than among those with grade I (7/57, 12.3%) or II (26/213, 12.2%)
tumors. HER-2 over-expression appears to be more prevalent in ER-negative patients

(44/209, 21.1%) than among ER-positive patients (42/318, 13.2%), and is more
prevalent in PR-negative patients (46/247, 18.6%) than in PR-positive patients
(37/275, 13.5%).

The mean age for patients with positive status was 57.35 as compared to 56.79 for

negative status and 59.35 for unknown status. Positive status was most prevalent in
the age group 50-59 (26/160, 16.3%) and least prevalent in the youngest age group,

age 25-39 (8/58, 13.8%). Differences in HER-2 status by age group were not

significant.
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Differences in treatment by surgery, hormone therapy, chemotherapy or radiation by

HER-2 status were unappreciable and insignificant.

Demographic Trends

As seen in Table 9, positive HER-2 status is slightly more prevalent (85/599, 14.2%)
in counties with a B/AA population proportion exceeding that of the state than in
counties at or below the state proportion (6/45, 13.3%). The number of unknown

values are greater in counties with more African-Americans (194/599, 32.4%) as

compared to counties with less (9/45, 20.0%). There is a statistically significant
difference in status by continuous County income, however due to small cell counts

the binary income variable is considered instead. Counties with a median income at
least as high as that of the State have a higher frequency of positive status

(37/214,17.3%) as compared to counties with a relatively lower income (54/430,

12.6%). Differences in HER-2 status by relative County racial composition and
income measures are not statistically significant.

Bivariate Correlations

As shown in Table 10, HER-2 testing correlated significantly with tumor size
(r=-0.096, P<0.05), negative PR status (r=-0.090, P<0.05), and County income (r=0.081, P<0.05). High and significant correlations included HER-2 testing with ER (r=0.505, P<0.01) and PR (r=0.519, P<0.01) testing, nodal testing (r=0.188, P<0.01) and

grade testing (r=0.150, P<0.01). Table 11 shows that HER-2 status is correlated

significantly and inversely with diagnosis year (r = -0.112, P<0.05).
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Univariate Regression

Of all variables tested independently for their association with HER-2 testing, the
variables ER testing (OR= 17.30, P<0.001), PR testing (OR= 19.50, P<0.001), nodal

testing (OR=2.65, P<0.001), grade testing (OR=2.63, P<0.001), and positive PR status

(OR=0.60, P=0.04) were significant. Residence in New Haven County was also
significant, with Hartford County as reference (OR=0.65, P=0.05). Increased age

(OR=0.99, P=0.07) and positive ER status (OR=0.61, P=0.06) met criteria for entry
into final models as well (Table 12).

Of the variables tested independently for their association with positive HER-2 status,
none were significant at the 0.05 level. Diagnosis year 2003 (OR= 0.50, P=0.06),

positive ER status (OR=0.63, P=0.05) and positive nodal status (OR=1.54, P=0.10)

approached significance and were eligible for inclusion (Table 13).

Multivariate Regression

Odds ratios for the association of selected clinicopathologic characteristics with HER-

2 testing are given in Table 14. Compared with patients residing in Hartford, tumors
of patients living in Fairfield County were 22.46 times as likely to be tested for HER-2
status (OR=22.46, 95%CI 1.68-300.32, P=0.02), controlling for age, diagnosis year,

ER testing, ER status, County median income, nodal status, tumor size, testing of
lymph nodes and testing of grade. The likelihood of HER-2 testing in either New

Haven County or in the combination County comprising Litchfield, Tolland, New
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London, Middlesex and Windham counties was comparable to likelihood of testing in

Hartford County. HER-2 testing did not vary significantly by patient age, diagnosis

year, ER status, County income, nodal status, tumor size, or grade testing. The Hosmer
and Lemeshow goodness of fit test statistic (P=0.93) suggested that the model fit the
data well.

When PR testing was added into the model in substitution for ER testing, results were

comparable to the model including ER testing. When analyzing according to
Medicare eligibility (age >65 versus <65), results were similar to when continuous

diagnosis year was used, showing residence in Fairfield County to significantly
increase likelihood of testing (OR=22.59, 95%CI 1.69-302.15, P=0.02) when

compared with Hartford County (referent). When excluding patients with distant
stage, results show that residence in Fairfield County increases likelihood of testing

by 25 times as compared to residence in Hartford (OR=25.08, 95%CI 1.87-337.17,

P=0.02), similar to results produced when all patients were considered.

Odds ratios for the association of patient characteristics with HER-2 status are given in

Table 15. Patients diagnosed in 2003 were significantly less likely to test positive

compared to patients in 2000 (OR=0.35, 95% CI 0.13-0.97, P=0.04). Positive HER-2
status did not vary by diagnosis age, grade, nodal status, ER status, tumor size,

histologic type, or County of residence. The Hosmer and Lemeshow test statistic

(P=0.89) indicated a satisfactory fit of the model to the data.
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DISCUSSION
We conducted a retrospective cross-sectional analysis to assess both the prevalence of
HER-2 testing and HER-2 positive status among the study population. We also
evaluated predictors of these two outcomes. Because of the established disparity in

prognosis between Black and White breast cancer patients in CT, 2 we chose to study
Black/African-American cases to determine the

prevalence of HER-2 testing as well

as HER-2 status of tumors among this sample of B/AA patients.

HER-2 Testing

Women who lived in Fairfield County were more likely to receive HER-2 testing than
those living in Hartford County when controlling for age, diagnosis year, ER testing,

ER status, County median income, nodal status, tumor size, lymph node testing and
grade testing. It is beyond the scope of this study to analyze potential reasons for this
disparity but discussion of income and other socio-economic factors may be
informative. The 1999 median household income of Fairfield residents was $65,249,
as compared to $50,756 in Hartford. 32 Fairfield County’s relatively high income may

contribute to its higher rate of testing. The differential in HER-2 testing may also be
attributed to a regional learning curve among physicians. As of 2000, testing for HER-

2 status was contingent upon the decision of the treating physician. 9 As increasing
research supports the prognostic value of the HER-2 tumor marker, it has likely
become more accepted by providers over time and increasingly considered a standard

of care. Trend in testing by County shows that testing is most prevalent in the
"d
Combined County, with Fairfield County showing the 2 highest rate of testing,

31

which may contradict the results of multivariate analysis. Trend in HER-2 testing for

all Counties by diagnosis year shows an increase in testing from 69% in 2001 to 78%
in 2003. This finding may support the results of a former retrospective analysis study

describing a two-fold increase in HER-2 testing from 1999 to 2000.19

In addition to time trend in testing, study results show that women having any reported
disease characteristics are more likely to have HER-2 testing reported. HER-2 testing
was administered more often among patients who also received steroid receptor

testing, lymph node examination, and examination of grade, compared to those who
did not reportedly receive these procedures. There is a high correlation among these
tests, suggesting a systematic trend in disease management among patients.

Patients with regional stage disease show higher frequency of testing then those with
either local or distant stage disease. The comparatively lower frequency of testing

among those with more advanced disease may reflect provider hesitance to undergo
non-routine diagnostic testing when poor prognosis has already been determined.

Testing occurred slightly more often among ER negative patients, at a rate of 88.5%
versus 82.4% compared to those with positive ER status. This finding is consistent

with results of a study that found negative ER status to be significantly associated with

HER-2 testing. 9 Although statistically significant, differences in test frequency by
other clinical characteristics were not substantial. The highest frequency of testing

(81%) appears in the youngest age group, women aged 25-29, while the lowest

frequency (68.9%) appears in the oldest group of patients, age 70 and over. Higher
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prevalence of testing in younger patients may reflect the fact that breast cancer tends
to be more aggressive in younger patients, prompting physicians to characterize the
tumor in detail. It could also reflect more up-to-date knowledge among younger

patients about current tests.

Similar findings among multivariate models including and excluding distant stage

patients suggest that physicians are not more or less inclined to utilize HER-2 testing
with the most advanced (metastatic) cases. However the small number of distant stage

patients (n=30) may invalidate any such conclusion. Models assessing Medicare
eligibility as a predictor of testing suggest that this factor does not appear to influence
testing.

To the best of our knowledge, there are no studies to date that have evaluated
population-based prevalence of HER-2 testing. Therefore, the 74.1% prevalence rate
found here may be a benchmark for future studies. We do not know if unknown HER-

2 information indicated the exclusion of the tumor marker from the diagnostic workup,
or if it reflected a lack of reporting. Further, it is unknown if HER-2 testing in this

group of patients is contingent upon clinical judgment or information. If all diagnostic
testing is performed simultaneously, then the observed prevalence may reflect that

among all B/AA breast cancer patients, regardless of other prognostic factors. If HER2 testing is performed subsequent to other tests, only high-risk patients may be
selected for testing. We attempted to determine the temporality of standard diagnostic

testing with respect to HER-2 testing but information in pathology reports was not
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complete enough to allow this. Therefore it is unknown if HER-2 testing was
influenced by knowledge of other prognostic factors.

HER-2 status

Women diagnosed in 2003 were significantly less likely than those diagnosed in 2000
to test positive for HER-2 when controlling for age, grade, nodal status, ER status,
tumor size, histologic type, and county of residence.

A significant and inverse

bivariate correlation between HER-2 status and diagnosis year supports this finding of
a decrease in positive status over time.

Reasons for this change need to be better understood. The decrease in prevalence may
be due to changes in pathological criteria for "positive" cut points, or to differences in
clinical staff. A decrease in positive status over time may also reflect an increased

frequency with which the test is utilized. As HER-2 testing becomes more routine, it
may be included in the diagnostic workup of a larger group of patients. If this larger
tested population includes more HER-2 negative patients, the proportion of HER-2

positive cases detected would decrease accordingly. However, the total number of

study patients tested for HER-2 increased from 110 in 2000 and 2001, to 131 in 2002
and 126 in 2003, a relatively small change in total tested cases. Therefore, the

observed decrease in positive status may not be explained by use of the test among a
bigger patient population.

Of those for whom HER-2 status is known, the percentage of positive status is 20.6%,
which is on the low end in comparison to the 20-40% rate reported among primary
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invasive breast cancer patients, 6’8 suggesting that HER-2 over-expression does not

explain the relatively poor survival among Black/African-American breast cancer
patients. A more conservative report, however, estimates that prevalence of HER-2 is
10-34% for women living in the United States. 26 One clinical study found that over-

expression of HER-2 occurs more frequently in Black women as compared to White
women, 10 yet we know of no related population-based studies. More research is
warranted to understand the prevalence of HER-2 status among Blacks/AfricanAmericans.

The 20.6% prevalence of positive HER-2 status observed may be inaccurate

depending on the process through which patients are chosen for testing. Results show
that HER-2 testing is performed more often with other standard diagnostic tests and
wih hormone receptor negativity than without. If HER-2 testing is performed

simultaneously with other diagnostic tests, then the observed prevalence may represent
the prevalence of HER-2 positive among all B/AA breast cancer patients. However, if

diagnostic tests are performed serially, with HER-2 testing subsequent to standard
tests, then the observed prevalence of positive status may be inflated. In the case of
serial testing, test results showing hormone receptor negativity, lymph node

involvement and high grade tumors would.likely influence a clinician to test for HER2. Patients with aggressive disease, rather than all patients, would be selected for

testing. The observed prevalence of positive status would therefore be artificially

high; representing the prevalence of HER-2 over-expression among a relatively highrisk group of patients.
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Test type
HER-2 status testing is a relatively new technique in clinical diagnostic centers. 17
There have been recommendations to standardize HER-2 testing procedures
6
nationally, and to retest ambiguous cases through additional assay. For instance, if

an IHC assay yields a questionable result (i.e. 2+), recommendations may be made

that the result be validated against another method such as FISH. 6 Of study patients
who were tested for HER-2 (n=477), test type was specified for 70.9% (n=338). The

overwhelming majority of these patients received IHC testing only (92.6%), as

compared to both IHC and FISH (6.8%) or FISH only (0.6%). The relative abundance
of IHC testing is likely attributable to difference in cost. Although the combination of

IHC with FISH is reported to be the most effective method of testing, the cost of FISH
is 28 times greater than IHC. 3 The average cost of IHC is $5.90 per patient, as

compared to an average FISH cost of $166.67. 3 Furthermore, FISH testing is not
4
available in all labs, and is considered to be technically difficult and time consuming.

Many advocate IHC as the primary test for identifying candidates for trastuzumab
because it is readily available, easily performed in most clinical pathology labs,

relatively inexpensive, and reliably tests for over-expression of trastuzumab’s
5
therapeutic target, the HER-2 protein. The gold standard of HER-2 evaluation has

been debated extensively, with complications due to inter-observer and inter-

laboratory variability.
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Our study provides strong evidence that FISH testing is still not adopted routinely.
Despite ongoing debate regarding whether IHC or FISH offers most the appropriate
technique for HER-2 status determination, it is certain that accurate assessment of
HER-2 status is essential to ensure that patients likely to benefit from trastuzumab

therapy are identified.

Clinicopathologic Comparisons with White Breast Cancer Patients

As compared to White patients, B/AA patients in our sample were younger at
diagnosis, suggesting that relatively poor prognosis among this African-American
population is not attributable to the confounding effects of old age. As compared to
White cases, B/AA cases generally had larger tumors and positive nodal status. This is
consistent with reports that African-American breast cancer patients are more likely to

have larger tumor size and lymph node involvement as compared to White women. 5
Black/African-American cases show a comparatively higher frequency of grade III/IV

tumors, ER-negative status and PR-negative status, supporting the reported association

of Black race with high-grade tumors and hormone-receptor negativity. 5 When

compared to White cases, more B/AA cases were reported to have ductal histology

(75% verus 69%, respectively). A statistically significant relationship between HER-2
over-expression and ductal carcinoma has been reported, 6 suggesting a higher risk of

poer outcome among B/AA cases compared to White cases.

The majority of B/AA patients lived in Hartford County, while the majority of White

patients lived in Fairfield County. Identification of differences by County is of
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interest as prognosis among breast cancer patients in CT reportedly varies not only by
racial category but by geographic location. 3 An evaluation of geographic differences
in survival during the 1984-1995 period found survival to be significantly worse for

cases living within 5 urban areas around the State, one of which was Hartford-East

Hartford. The median Fairfield County income, $65,249, exceeds that of Hartford by

$14,493, a difference that may predispose Fairfield residents to more comprehensive
disease management. Approximately the same frequency of ER testing, PR testing,

lymph node examination and grade assessment was reported for both groups,
suggesting no difference in standard care according to race. The groups did not differ
appreciably by diagnosis year, stage, number of positive lymph nodes, surgery,
radiation therapy or laterality.

Although HER-2 positive status of the study population falls within the low-end of the
range reported for the general population, comparison of B/AA cases with SEER
White cases shows a disproportionately high presence of other adverse prognostic

factors among study cases. Study cases present with larger and higher-grade tumors
than SEER White patients, and are more frequently reported to be lymph-node

positive, hormone-receptor negative, and to have ductal histology. Further, B/AA
cases more frequently reside in relatively-lower income areas, which may impact

disease management.

Significant differences in survival between White and Black breast cancer patients
have been observed after controlling for clinicopathologic and demographic factors. ’4
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To our knowledge these studies have not accounted for frequency of HER-2 testing.
The next phase of the current study aims to collect HER-2 data on White cases
otherwise meeting inclusion criteria. It is recommended that frequency of HER-2

testing and over-expression as well as established prognostic factors among White

patients be evaluated for comparison to trends found here. Differences in testing

prevalence by race may indicate social disparities in breast cancer management,
deserving of thorough investigation. Differences in rate of over-expression by race

may point to biological origins of survival disparity. Alternatively, lack of difference
in HER-2 positivity by race may lend support to suspicions that race is a surrogate for

other determinants of aggressive breast carcinoma, at which point would exclude

HER-2 over-expression.

Strengths
Study strengths include the use of a statewide, population-based cancer registry. The
use of state cancer registries has reportedly produced extensive and high-quality data

for evaluating the cancer burden due to their large size and completeness. 37 The ability
to obtain a relatively large sample of all Black/African-American breast cancer

patients in CT increases the validity of current findings and will enable a sample of an

equally large size to be selected from eligible White patients in Phase II. Another
strength involves the threshold used to indicate high correlation. While a correlation of
0.90 has been reported to indicate risk of multi-collinearity, 38 the current study used
the more conservative value of 0.70, and assumed high correlation for parameter
estimates with coefficient values exceeding this value. The small size of several
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counties was addressed by collapsing counties with less than 30 residents into one

category, resulting in four total County categories. The collapse was done to increase

power for statistical analysis and to facilitate interpretation of results.

The study benefits from its inclusion of SEER Summary Stage in descriptive analyses,
a measure designed specifically for cancer surveillance with longitudinal stability for

population-based registries. Summary staging is reportedly less complex than other
staging systems and useful for small series of cases for which only general categories

produce enough data for meaningful analysis. 23 Division of study cases by Summary

Stage still resulted in small categories needing further collapse, yet other staging
systems may have required more drastic collapse to sufficiently increase group
numbers. The Collaborative Staging System allows data collectors to record regional

lymph nodes as "negative" and distant metastastis as "none" rather than coding each
field as unknown, as was required in previous sytems. 23 Such increased specificity

results in a stage category representing relatively accurate information.

Limitations

Several limitations deserve mention. There are potential inaccuracies in variable

coding, as well as subjectivity involved in selection of variable referent categories.

Any interpretation of results involving geographic location should be done with
discretion, as County is only a crude estimate of a patient’s location. Demographic

characteristics may vary widely within each County. The model-building strategy
used to obtain final models excluded steps that may have been necessary for accurate
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results. Interactions between variables were not tested; therefore, any interactions

present were not addressed and may have skewed statistical analysis. Additionally,
neither confounding nor influential observations were assessed. The substantial

number of unknown or missing values for several variables reduces statistical power
in the case of regression analyses, in which all unknown values were set to missing.

The consideration of numerous independent variables resulted in a high number of
cases being excluded from analysis. The reduction in number of selected cases

resulted in the variables ER testing, PR testing, lymph node testing, and grade testing

being constant for all cases and thus removed from forward stepwise analysis of
predictors of HER-2 testing. In the final model predicting HER-2 testing, the variables

ER testing, PR testing, and lymph node examination were similarly found to be
constant and removed from analysis.

Significant covariates resulting from univariate versus multivariate regression analyses
for each outcome were inconsistent. Univariate analysis showed ER testing, PR

testing, PR status, residence in New Haven County, lymph node testing and grade
testing to be significantly associated with HER-2 testing, yet multivariate analysis
showed only residence in Fairfield County to significantly influence likelihood of

testing. Results for the outcome HER-2 status also differed. Univariate analyses
showed no variables to be significant at the 0.05 level, while multivariate analysis
showed diagnosis year 2003 to significantly influence HER-2 status. Such

inconsistency may indicate problems with the data. Other limitations may result from

global variation in the degree of IHC staining considered to be HER-2 positive. IHC
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interpretation relies on a qualitative scoring system on a scale of 0-3+.

22

A tumor

biopsy of 2+ may be considered either borderline or indicative of over-expression.
The currently study considered IHC scores of _>2+ to be HER-2 positive, yet other
studies have considered only IHC scores of 3+ to be positive. Exclusion of IHC 2+

patients from the positive cases would drastically influence results.

Several variables of interest were unavailable for analysis. Information previously
shown to be associated with HER-2 testing such as insurance type and physician

specialty 9 was not present in the dataset, and neither were measurements of
established and suspected risk factors for breast cancer, such as parity, 39 late age at
first full-term pregnancy, 39 history of breastfeeding, 4 or oral contraceptive use. These

have been shown to not be associated with HER-2 over-expression,2 but further study

may be warranted. Limitations also exist in the comparison of study data with SEER
data. There are some SEERStat variables, such as histologic type, for which value

frequencies do not add up to 100%. This may indicate either missing data or
inappropriate variable categorization. Also, the source of information for the study
and for SEERStat differed for two variables; tumor size and SEER summary stage

2000. While SEERStat refers to tumor size as "item #780 1988+", the study variable
was labeled according to the SEER 2004 manual coding for "CS tumor size, #2800".

The SEER summary stage 2000 variable represents the years 1998+ according to

SEERStat, but represents the years 2001 / according to the SEER 2004 manual. This
inconsistency may indicate inaccuracy in study information for patients diagnosed in
2000. ER and PR status were pre-coded in both SEERStat and the CTR database and

42

so the coding source is unknown. Otherwise, information sources for variable coding
were consistent between SEERStat and study variables. Hormone therapy and

chemotherapy were not found in the SEERStat variable list and so this information is
not presented.

The use of the SEER 2004 manual for variable coding assumes unchanged coding

guidelines from those applicable to study cases diagnosed between 2000 and 2003, as
the SEER 2004 coding manual is effective for cases diagnosed January 1, 2004 and

forward. 2 Reported 2004 revisions include replacement of EOD (extent of disease)
with Collaborative Stage, changes in instructions and definitions for the race coding

field, and the addition of instructions for collecting and abstracting the benign and
borderline primary intracranial and central nervous system tumors. 23 The current study
uses both EOD variables and

Stage for various analyses. However, the exclusion of

Stage from multivariate models eliminates the possibility of interactions or
collinearity. Intracranial and central nervous system tumors are irrelevant to the study,
yet changed race definitions may decrease the reliability of observed Black race
values. Although not obvious during the course of variable labeling/modification,
inaccuracies may otherwise exist in variable coding given the application of the 2004

guidelines to data collected for cases diagnosed between 2000 and 2003.

CONCLUSIONS
Further research is warranted in several areas. It is not known if frequency of HER-2

testing observed among this study population reflects actual rate of testing, or
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underreporting in the pathology report. Data gathered for more recent diagnosis years
would be useful in evaluating the evolution of both the practice and reporting of HER2 testing in CT. Time trend in testing prevalence should be monitored to assess the

acceptance of HER-2 testing as a standard of care, and the extent to which HER-2

testing correlates with other facets of standard treatment.

Whether or not a patient is tested for HER-2 may be influenced by numerous factors

including geographic location and regional wealth. Testing differences may reflect
variation in patient-provider communication, patients’ understanding of HER-2, or

cultural influence on perception and willingness to accept testing. Potential barriers to

testing may exist above and beyond economic considerations and deserve evaluation.
Research into social and cultural influences on HER-2 testing may lend insight into

any observed testing patterns.

Efforts should also be made to determine if HER-2 testing is performed

simultaneously with or subsequent to routine diagnostic tests. This knowledge would
allow more accurate interpretation of observed prevalence of HER-2 over-expression

by identifying the tested patient population. If clinicians are testing only those
patients for whom poor prognosis has been established, then observed prevalence of
HER-2 over-expression would be artificially high; representing the prevalence among
a high-risk population. If all diagnostic tests are performed simultaneously, calculated
rate of positive status would reflect that among breast cancer patients regardless of

prognosis.
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Current results indicate that a large proportion of the study population is being tested
for HER-2, yet the impact of test results on clinical judgment and patient treatment is
undetermined. Results show lack of association between HER-2 status and

chemotherapy, surgery, hormone therapy or radiation, raising the question of whether
or not HER-2 testing influences breast cancer treatment. Medical management

regarding testing and post-test treatment may vary depending on numerous factors
which have yet to be assessed. In addition to determining why certain patients are not

tested, it is of importance to evaluate the impact of testing on the treatment of tested
women, and if the process of testing and treatment varies systematically among

patients.

Our findings suggest that HER-2 testing may be determinable to some extent, but did
not shed new light on risk factors for HER-2 positivity. Continuous efforts should be

made to collect extensive biologic, social and demographic data for this and other

populations in order to evaluate potential determinants of HER-2 over-expression. We
do not, however, recommend using CTR pathology reports to estimate prevalence of

HER-2 testing or status until their reliability has been established by other research.

Ongoing surveillance of disease survival has been recommended to better determine
the reasons for disparity among racial groups in terms of mortality from breast cancer.

Cases in our study presented with a rate of HER-2 positivity that is low when

compared to the reported range for the general population, suggesting that HER-2
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expression does not explain poor relative prognosis among this group. It could be that
Black/African-American patients who are positive for HER-2 have a worse prognosis

than their White HER-2 positive counterparts due to disadvantages related to
undetermined biologic factors or social conditions. We recommend conducting a study

similar to ours among a sample of White breast cancer patients, matched on age, stage

and other key social factors. Examination of results may reveal systematic differences
in testing patterns or trends in biologic factors including HER-2, which may help to

explain the established disparity in survival between Black and White breast cancer

patients. Identified differences in testing may drive implementation of standard
institutional policies for universal improvement in quality of care for all patients.
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APPENDICES
Appendix 1. Patient Information Abstraction Form
Patient ID:

Study ID:

Date of Chart Review:
HER2 Information
+

None done [0]

+

Positive 1]

+

Negative [2]

+

Borderline 3]

+

Ordered but not in chart [88]

+

Unknown [99]

HER2 Test Method
+

IHC only [1]

+

FISH only [2]

+

Both 3]

+

Unknown [99]

HER2 Test Value
+

IHC [value]

+

FISH [value]

Laboratory Used
+

Internal 1]

+

External Lab[2]

+

Unknown [99]

Date of HER2 Test
Date

+ Unknown

Tamoxifen used

47

+

Yes Ill

+

No[2]

+

Unknown [99]
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Appendix 2. Data Dictionary

IEM

LEVELS

CTR ID (Patient ID)
Random ID
Race

Deleted when file is complete

2

Date of Abstract
HER2 information *

CREATE VARIABLE

White
Black

Date
0= None done

Jess

1= Positive
2= Negative
3= Borderline
88 Ordered but not in chart
99 Unknown

HER2 test method

HER2 test source

SOURCE
CTR file
Dr. Swede
CTR file

HER2 test
0 None done

Path

Report

=P,N,B
88 Ordered
99 =Unknown

Letter to
Hospital

IHC
2= FISH
3= Both
99= Unknown
l= Hospital Path Lab
2= External Path Lab
99= Unknown

and Path

Report
Letter to
Hospital
and Path

Report
HER2 scoring scheme

HER2 testing initiated

IHC intensity
2 IHC % cut-point
3 FISH Pos/Neg
4 FISH ratio
99 Unknown

Letter to

Year

Letter to

Hospital
and Path

Report
Hospital
and Path

Report
Hospital

ER value*

PR value*

Date of birth
Date of diagnosis
TNM stage at diagnosis
Vital status

Date of last follow-up
or death
[CD- 10 Cause of death

Code
0= None done
Positive
2= Negative
3= Borderline
88 Ordered but not in chart
99 Unknown
0= None done
l= Positive
2= Negative
3= Borderline
88 Ordered but not in chart
99 Unknown
Deleted when age zalculated

I, II, III, IV
Alive
4= Dead
Unknown
Month and Year

ER test
0 None done
-P,N,B

CTR file
CTR file

88 Ordered
99 =Unknown

PR test
0 None done
=P,N,B

CTR file

88 Ordered
99 =Unknown

Age

CTR file
CTR file
CTR file
CTR file
CTR file

0000 Alive at last follow-up
ICD code
7777=death cert. unavailable
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CTR file

7797=death cert. avail, but no code

CTR file

Start date of primary
treatment

Tamoxifen used (yes,

Path

no)

Report or

Town
Histological type
Histological grade

ICD-0-3 code

I, II, III

Size of tumor
Nodal status
* Value levels used by NAACCR and SEER for tumor markers

5O

CTR file
CTR file
CTR file
CTR file
CTR file
CTR file
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TABLES

Table 1. Clinicopathologic and Demographic Characteristics of Study Participants

(n=644)
n(%)
Diagnosis age
Mean

57.68 yrs
29-106 yrs

Range
Medicare eligible

437 (67.9)
207 (32.1)

<65 yrs
>65 yrs
Age at diagnosis
25-39
40-49
50-59
60-69
>70
Year of diagnosis
2000
2001
2002
2003
County of residence
Hartford

58(9.0)
155 (24.1)
160 (24.8)
120 (18.6)
151 (23.4)
146 (22.7)
159(24.7)
178 (27.6)
161 (25.0)

213(33.1)
194(30.1)
192 (29.8)
45 (7.0)

Fairfield

New Haven
Combined*
County income,
Median income < CT
Median income > CT

430(66.8)
214 (33.2)

County composition
Percent B/AA < CT
Percent B/AA > CT
ER tested

45 (7.0)
599 (93.0)
543 (84.3)
101 (15.7)

UnknownS[
PR tested

544 (84.5)
00 5.5)

Unknown#
Lymph nodes tested
Yes

517 (80.3)
127 (19.7)

Unknown
Grade tested

Yes

575 (89.3)
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69 (10.7)

Unknown

Tumor size
289 (44.9)
225 (34.9)
61 (9.5)

<2cm
>2cm, <5cm
>5cm
Unknown
Histology
Ductal and related
Lobular
Mixed ductal and lobular

69(10.7)
484 (75.2)
36 (5.6)
48 (7.5)

76(11.8)

Unknown/other

SEER summary stage
Local
Regional

379(58.9)
215 (33.4)

Distant
Unknown
Positive lymph nodes
0
I-4

30(4.7)
20 (3.1)

5+
Unknown
Nodal status

45 (7.0)
133(20.7)

312 (48.4)

154(23.9)

199 (30.9)
312 (48.4)
133 (20.7)

Positive

Negative
Unknown
Grade

57 (8.9)

II

213(33.1)
304 (47.2)
70(10.9)

Ill/IV

Unknown

ER status* *
Positive

318(49.4)

Negative

209 (32.5)
117 (18.2)

Unknown

PR status**
275 (42.7)
247 (38.4)

Positive

Negative
Unknown

122(18.9)

Surgery
590 (91.6)
54 (8.4)

Site specific/resection
None
Hormone therapy

Any
None

94 (14.6)
530(82.3)
20 (3.1)

Unknown

Chemotherapy

Any
None

253 (39.3)

373(57.9)
8 (2.8)

Unknown
Radiation

Any
None

261 (40.5)
361 (56.1)
22 (3.4)

Unknown

Laterality

56

’Right origin of primary

329 (51.1)
313 (48.6)
2 (0.4)

Left origin of primary
Unspecified/unknown
Vital Status

526(81.7)
118 (18.3)

Alive
Dead

* Counties with population counts <30 (n=5; Litchfield, Toiland, Middlesex, New London,
Windham) collapsed into "Combined".
Based on 2000 U.S. Census data.
Median household income in U.S. dollars (1999) relative to that of CT.
County % B/AA relative to CT proportion as a whole (9.1%)
Includes reports showing a test result and a test order.
ql Includes report of "test not done" (n=22).
# Includes report of"test not done" (n=20).
** Positive status includes only reports explicitly stating positive. Negative includes report of
negative. Unknown includes report of unknown, uncertain, test ordered only, test not done.

"
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Table 2. HER-2 Characteristics of Study Participants (n=644)
n(%)
HER-2 tested
477 (74.1)
167 (25.9)

Yes*

UnknownS
HER-2 Status
Positive
Negative/borderline

91 (14.1)
350 (54.3)
7 (1.1)
196 (30.4)

Conflicting IHC
Order only/unknown
HER-2 test type
IHC only
FISH only

313 (48.6)
2 (0.3)
23 (3.6)
306 (47.5)

Both
Unknown

Includes reports showing a test result and a test order.
Includes all reports with no evidence of HER-2 testing.
As determined by any type of test.

Table 3. Comparison of Characteristics among Study Participants and Breast
Cancer Patients in the SEER Database, 2000-2003
SEER Black
cases (n=651
n (%)

Study cases
(n=644)
n (%)

57

SEER Whit
cases

(n=10,199)

Medicare eligible
<65 yrs
>65 yrs

437 (67.9)
207 (32.1)

438 (67.3)
213 (32.7)

5,488 (53.8)
4,711 (46.2)

58(9.0)
155(24.1)
160 (24.8)
120 (18.6)
151 (23.4)

57 (8.8)
154 (23.7)
163 (25.0)
122 (18.7)

495 (4.9)

155(23.8)

1,739(17.1)
2,248 (22.1)
1,961 (19.2)
3,753 (36.8)

146
159
178
161

(22.7)
(24.7)
(27.6)
(25.0)

148(22.7)
160(24.6)
181 (27.8)
162(24.9)

2,611 (25.6)
2,727 (26.7)
2,505 (24.6)
2,356 (23.1)

213(33.1)
194 (30.1)
192 (29.8)
45 (7.0)

213(32.7)
198 (30.4)
191 (29.3)
46 (7.1)

2,485
2,643
2,482
2,523

543 (84.3)
101 (15.7)

534 (82.0)
117 (18.0)

8399(82.4)
1800 (17.7)

544 (84.5)
00 ( 5.5)

534 (82.0)
117 (18.0)

8367 (82.0)

517 (80.3)
127 (19.7)

512 (78.6)

139(21.4)

7862(77.1)
2337 (22.9)

575 (89.3)
69 (10.7)

578(88.8)
73 (11.2)

9037 (88.6)
1162 (11.4)

289 (44.9)
225 (34.9)
61 (9.5)
69 (10.7)

291 (44.7)
231 (35.5)

5731 (56.2)

53(8.1)
67 (10.3)

592 (5.8)
941 (9.2)

484 (75.2)
36 (5.6)
48 (7.5)

489 (75.1)
37 (5.7)
46 (7.1)

76(11.8)

16(2.5)

7059(69.2)
1007 (9.9)
1004 (9.8)
212(2.1)

379(58.9)

384(59.0)
213(32.7)
3 (4.8)
23 (3.5)

6,554 (64.3)
2,933 (28.8)
433 (4.3)
279 (2.7)

312 (48.4)
154 (23.9)
45 (7.0)
133 (20.7)

315 (48.4)
152 (23.4)
45 (6.9)

139(21.4)

5, 64 (50.6)
2,096 (20.6)
602 (5.9)
2,337 (22.9)

199 (30.9)
312 (48.4)

197 (30.3)
315 (48.4)

2,698 (26.5)
5,164 (50.6)

Age at diagnosis
25-39
40-49
50-59
60-69
>70
Year of diagnosis
2000
2001
2002
2003
County of Residence
Hartford
Fairfield

New Haven
Combined*
ER tested

Yes?
Unknown

(24.4)
(25.9)
(24.3)
(24.7)

PR tested

YesJ"
Unknown
Lymph nodes tested
Yes
Unknown
Grade tested

Yes
Unknown
Tumor size
<2cm
_>2cm, <5cm
>5cm
Unknown
Histology
Ductal and related
Lobular
Mixed ductal and lobular
Unknown/other

1832(18.0)

2834(27.8)

SEER summary stage
Local
Regional
Distant
Unknown
Positive lymph nodes
0
1-4
5+
Unknown
Nodal status
Positive

Negative

215 (33.4)
30 (4.7)

20(3.1)

58

Unknown
Grade

II
III/IV

Unknown

ER status

I1

Positive
Negative
Unknown

PR status
Positive

1

Negative
Unknown

133 (20.7)

139 (21.4)

2,337 (22.9)

57 (8.9)
213 (33.1)
304 (47.2)
70 (10.9)

54 (8.3)
219 (33.6)
305 (46.9)
73 (11.2)

1,397
4,081
3,559
1,162

318 (49.4)
209 (32.5)
117 (18.2)

320 (49.2)
214 (32.9)
117 (18.0)

6,690 (65.6)
1,709 (16.7)
1,800 (17.7)

275 (42.7)
247 (38.4)
122 (18.9)

276 (42.4)
258 (39.6)
117 (18.0)

5,645 (55.3)
2,722 (26.7)
1,832 (18.0)

590 (91.6)
54 (8.4)
0 (.0)

594 (91.2)
54 (8.3)
3 (0.5)

9,084 (89.1)
1,049 (10.3)
66 (0.6)

261 (40.5)
361 (56.1)
22 (3.4)

262 (40.2)
363 (55.8)
26 (4.0)

4,376 (42.9)
5,503 (54.0)
320 (3.1)

329(51.1)
313 (48.6)
0
2 (0.4)

335(51.5)
311 (47.8)
0(.0)
5 (0.8)

4,910(48.1)
5,141(50.4)
6 (0.)
142 (1.4)

526 (81.7)
118 (18.3)

571 (87.7)
80 (12.3)

9,223 (90.4)
976 (9.6)

(13.7)
(40.0)
(34.9)
(11.4)

Surgery
Site specific/resection/any
None

Unknown
Radiation

Any
None
Unknown
Laterality
Right origin of primary
Left origin of primary
Bilateral
Un speci fi ed/u nk n own
Vital Status
Alive
Dead

* Counties with population counts <30 (n=5; Litchfield, Tolland, Middlesex, New London,
Windham) collapsed into "Combined".
Includes reports showing a test result or a test order.
Includes report of"test not done" (n=22).
Includes report of"test not done" (n-20).
Positive status includes only reports explicitly stating positive. Negative includes report of
negative. Unknown includes report of unknown value, uncertain value, test ordered only, test not
done.

Table 4. Clinicopathologic Characteristics of Black/African-American Breast
Cancer Patients (n=644) by HER-2 Testing,* Connecticut Tumor Registry, 20002003
P-value ]1
HER-2 Tested"
Unknown{ (n=167)

,

(n=477)
Diagnosis age
Mean (yrs)
Medicare eligible
<65 yrs
>65 yrs

57.08

59.37

0.07

329 (75.3%)
148 (71.5%)

108 (24.7%)
59 (28.5%)

0.31

59

0.40

Age at diagnosis
25-39
40-49
50-59
60-69
>70
Year of diagnosis
2000
2001
2002
2003

11 (19.0%)
39 (25.2%)
42 (26.3%)
28 (23.3%)
47 (31.1%)

47 (81.0%)
116 (74.8%)

118(73.8%)
92(76.7%)
104 (68.9%)

0.31

110(75.3%)
110 (69.2%)
131 (73.6%)
126(78.3%)

36(24.7%)
49(30.8%)
47 (26.4%)
35 (21.7%)

161 (75.6%)
151 (77.8%)
128 (66.7%)
37 (82.2%)

52 (24.4%)
43 (22.2%)
64 (33.3%)
8 (7.8%)

454(83.6%)
23(22.8%)

89(16.4%)
78 (77.2%)

456 (83.8%)
21 (21.0%)

88 (16.2%)

79(79.0%)

404 (78.1%)
73 (57.5%)

113 (21.9%)
54 (42.5%)

439(76.3%)
38(55.1%)

136(23.7%)
31 (44.9%)

0.03

County of Residence
Hartford
Fairfield

New Haven

Combinedq[
ER tested

Yes?
Unknown#
PR tested

Yes
Unknown**

<0.001

<0.001

<0.001

Lymph nodes examined

Yes
Unknown
Grade tested

Yes
Unknown

<0.001

Tumor size

<0.001

186(82.7%)
45(73.8%)
36(52.2%)

79(27.3%)
39(17.3%)
16(26.2%)
33(47.8%)

358 (74.0%)
31 (86.1%)
36 (75.0%)
52 (68.4%)

126 (26.0%)
5 (13.9%)
2 (25.0%)
24(31.6%)

Local

278 (73.4%)

Regional

170(79.1%)
19(63.3%)
0 (50.0%)

101 (26.6%)
45 (20.9%)
11 (36.7%)
0 (50.0%)

<2cm
>2cm, <5cm
>5cm
Unknown
Histology
Ductal and related
Lobular
Mixed ductal/lobular
Unknown/other

210 (72.7%)

0.26

SEER summary stage
Distant
Unknown
Positive lymph nodes
0
1-4

5+
Unknown
Nodal status
Positive

Negative
Unknown
Grade

0.01

<0.001

71 (22.8%)

241 (77.2%)
125 (81.2%)
35 (77.8%)

29(18.8%)
10(22.2%)
57 (42.9%)

76(57.1%)

<0.001

76(57.1%)

39(19.6%)
71 (22.8%)
57 (42.9%)

44 (77.2%)

13(22.8%)

160 (80.4 %
241 (77.2%)

0.001

60

II
III/IV

Unknown

159 (74.6%)
236 (77.6%)
38 (54.3%)

54 (25.4%)
68 (22.4%)
32 (45.7%)

262 (82.4%)
85 (88.5%)
30 (25.6%)

56 (17.6%)
4 ( .5%)
87 (74.4%)

225 (81.8%)
218 (88.3%)
34 (27.9%)

50 (18.2%)
29 (11.7%)
88 (72.1%)

443 (75.1%)
34 (63.0%)

147 (24.9%)
20 (37.0%)

63 (67.0%)
399 (75.3%)
5 (75.0%)

31 (33.0%)
131 (24.7%)
5 (25.0%)

201 (79.4%)
262 (70.2%)

52 (20.6%)
111 (29.8%)

14(77.8%)

4(22.2%)

201 (77.0%)
260 (72.0%)

16(72.7%)

60 (23.0%)
101 (28.0%)
6(27.3%)

243 (73.9%)
232 (74.1%)
2 (100%)

86 (26.1%)
81 (25.9%)
0 (.0%)

ER status
Positive

Negative
Unknown

<0.001

PR status
Positive

Negative
Unknown

<0.001

Surgery
Site specific/resection

None
Hormone therapy
Any
None
Unknown

0.05

0.24

0.03

Chemotherapy

Any
None
Unknown
Radiation

Any
None
Unknown
Laterality
Right origin of primary
Left origin of primary

Unspecified/unknown

0.37

0.87

* By any type of test.

"

Includes reports showing a test result and a test order.
Includes all reports with no evidence of HER-2 testing.
Pearson chi-squared test for proportions, t-test of independent samples for mean values.
Asymp.Sig (2-sided).
Counties with population counts <30 (n=5; Litchfield, Tolland, Middlesex, New London,
Windham) collapsed into "Combined".
# Includes report of "test not done" (n=22).
** Includes report of "test not done" (n=20).
?" Positive status includes only reports explicitly stating positive. Negative includes report Of
negative. Unknown includes report, of unknown value, uncertain value, test ordered only, test not
done.

I

Table 5. Time Trend in HER-2, ER, and PR Testing among Black/AfricanAmerican Breast Cancer Patients (n=644), Connecticut Tumor Registry, 2000-2003
2003
2000
2001
2002
P-value*,
HER-2

0.31

tested
61

36 (24.7%)

lO (69.2%)
49 (30.8%)

131 (7_.6%)
47 (26.4%)

126
35 (21.7%)

127 (87.0%)
19 (13.0%)

129 (81.1%)
30 (18.9%)

151 (84.8%)

27 (15.2%)

136 (84.5%)
25 (15.5%)

127 (87.0%)
19 (13.0%)

130 (81.8%)
29 (18.2%)

150 (84.3%)
28 (15.7%)

137 (85.1%)
24 (14.9%)

’llO (75.3%)

(78.3)

ER tested

0.56

Yes
Unknownq[
PR tested

Yes
Unknown#

0.65

* Pearson chi-squared test for proportions.

"f Asymp.Sig (2-sided).
:By any type of test.

Includes reports showing a test result or a test order.

all reports with no evidence of HER-2 testing.
I1 Includesreport
of "test not done" (n=22).

Includes

#Includes report of "test not done" (n=20).

Table 6. Geographic Trend in HER-2, ER, and PR Testing among Black/AfricanAmerican Breast Cancer Patients (n=644) by County, Connecticut Tumor Registry,
2000-2003
Harford
Fairfield
New Haven
PCombined *
(n=213)

(n= 194)

(n= 192)

(n=45)

161 (75.6%)
52 (24.4%)

151 (77.8%)
43 (22.2%)

128 (66.7%)
64 (33.3%)

37 (82.2%)
8 (17.8%)

HER-2 tested

Unknownq[
ER tested

Unknown#

0.09

183 (85.9%)
30 (14.1%)

157 (80.9%)
37 (19.1%)

160 (83.3%)
32 (16.7%)

183 (85.9%)
30 (14.1%)

157 (80.9%)
37 (19.1%)

161 (83.9%)
31 (16.1%)

43 (95.6%)
2 (4.4%)

PR tested

Unknown**

value
0.03

0.09
43 (95.6%)
2 (4.4%)

* Counties with population counts <30 (n=5; Litchfield, Tolland, Middlesex, New London,
Windham) collapsed into "Combined".
Pearson chi-squared test for proportions.
Asymp.Sig (2-sided).
By any type of test.
Includes reports showing a test result or a test order.
Includes all reports with no evidence of HER-2 testing.
#Includes report of"test not done" (n=22).
** Includes report of"test not done" (n=20).

"

l[

62

Table 7. Distribution of HER-2 Testing* by County Characteristics of
Black/African-American Breast Cancer Patients (n=644), Connecticut Tumor
Registry, 2000-2003

Unknown (n=167)

HER-2 Tested
(n=477)

P-value’

, ][

0.20

County

Composition,#
Percent B/AA < CT
Percent B/AA > CT
County income ,**
Median income < CT
Median income > CT

8 (17.8%)
159 (26.5%)

37 (82.2%)
440 (73.5%)

0.22

118 (27.4%)
49 (22.9%)

312 (72.6%)
165 (77.1%)

* By any type of test.
"[" Includes reports showing a test result or a test order.
Includes all reports that did not show evidence of HER-2 testing.
Pearson chi-squared test for proportions.
Asymp.Sig (Z-sided).
][ Based on 2000 U.S. Census data
# County % B/AA relative to CT proportion as a whole (9.1%)
** Median household income in U.S. dollars (1999) relative to that of CT.

I[

Table 8. Clinicopathologic Characteristics of Black/African-American Breast
Cancer Patients (n=644) by HER-2 status,* Connecticut Tumor Registry, 2000-2003
Positive
-value ll,7/
Negative
Unknown
’(n=91
(n=203)
(n=350)
Diagnosis age
Mean (yrs)
Medicare eligible
<65 yrs
>65 yrs
Age at diagnosis
25-39
40-49
50-59
60-69
>70
Year of diagnosis
2000
2001
2002
2003
County of
Residence
Hartford
Fairfield

New Haven
Combined**

57.35

56.79

59.35

65 (14.9%)
26 (12.6%)

242 (55.4%)
108 (52.2%)

130 (29.7%)
73 (35.3%)

8 (13.8%)
22 (14.2%)
26 (16.3%)
13 (10.8%)
22 (14.6%)

37 (63.8%)
86 (55.5%)
85 (53.1%)
68 (56.7%)
74 (49.0%)

13 (22.4%)
47 (30.3%)
49 (30.6%)
39 (32.5%)
55 (36.4%)

25
29
22
15

79 (54.1%)
77 (48.4%)
100 (56.2%)
94 (58.4%)

42 (28.8%)
53 (33.3%)
56 (31.5%)
52 (32.3%)

0.09#
0.34

0.62

0.24

(17.1%)
(18.2%)
(12.4%)
(9.3%)

0.01

28 (13.1%)
36 (18.6%)
21 (10.9%)
6 (13.3%)

124 (58.2%)
104 (53.6%)
92 (47.9%)
30 (66.7%)

63

6! (28.6%)
54 (27.8%)
79 (41.1%)
9 (20.0%)

<0.001

Tumor size
<2cm
>2cm, <5cm
>5cm
Unknown

Histology
Ductal and related
Lobular
Mixed
ductal/loblar
Unknown/other

35(12.1%)
39(17.3%)
8 (3.%)
9 (13.0%)

156 (54.0%)
136 (60.4%)
34 (55.7%)
24 (34.8%)

98(33.9%)
50(22.2%)
19(31.1%)
36(52.2%)

75 (5.5%)
5 (13.9%)

5(10.4%)

257 (53.1)
25 (69.4)
29 (60.4)

152(31.4%)
6(16.7%)
14 (29.2%)

6 (7.9)

39(51.3)

31 (40.8%)

0.13

SEER summary
stage
Local
Regional
Distant
Unknown
Positive lymph
nodes
0
1-4
5+
Unknown
Nodal status
Positive
Negative
Unknown
Grade

II
Ill/IV

Unknown

0.11

47 (12.4%)

36(16.7%)
4(13.3%)
4 (20.0%)

207 (54.6%)
123 (57.2%)
14 (46.7%)

6(30.0%)

125 (33.0%)
56(26.0%)
12 (40.0%)
0 (50.0%)
0.001

38 (12.2%)
28 (18.2%)

8(17.8%)
17 (12.8%)

184(59.0%)
86(55.8%)
27 (60.0%)
53(39.8%)

90(28.8%)

36(18.1%)
38 (12.2%)
17 (12.8%)

113(56.8%)
184 (59.0%)
53(39.8%)

50(25.1%)
90(28.8%)
63 (47.4%)

7 (12.3%)

33(57.9%)
122 (57.3%)
165 (54.3%)
30(42.9%).

17 (29.8%)
65 (30.5%)

40 (26.0%)

10(22.2%)
63 (47.4%)
<0.001

0.01

26(12.2%)
53(17.4%)
5(7.1%)

86(28.3%)
35 (50.0%)

ER status

<0.001

42(13.2%)
44 (21.1%)
5 (4.3%)

203(63.8%)
133(63.6%)
14(12.0%)

73(23.0%)
32(15.3%)
98(83.8%)

Positive

37 (13.5%)

Negative

46(18.6%)
8 (6.6%)

175(63.6%)
160 (64.8%)
15 (12.3%)

63 (22.9%)
41 (16.6%)

82 (13.9%)

326(55.3%)

182 (30.8%)

9(16.7%)

24 (44.4%)

2 (38.9%)

(.3%)
83(15.7%)
3 (.0%)

53 (56.4%)
286 (54.0%)

36(38.3%)
161 (30.4%)
6 (30.0%)

37 (14.6%)
52 (13.9%)

151 (59.7%)
189 (50.7%)

65 (25.7%)
132 (35.4%)

2(.%)

10(55.6%)

6(33.3%)

33(12.6%)

148(56.7%)

80(30.7%)

Positive

Negative

Unknown:
PR status

Unknown

<0.001

99(81.1%)

Primary surgery
Site

0.31

spec./resection

None
Hormone therapy

Any
None
Unknown

Chemotherapy
Any
None
Unknown
Radiation

An,,),

0.10

(55.0%)

0.14

0.81

64

54
4 (18.2%)

(15.0%)

190 (52.6%)
12 (54.5%)

117 (32.4%)
6 (27.3%)

54 (16.4%)
36 (11.5%)

173 (52.6%)
176 (56.2%)

102 (31.0%)
101 (32.3%)

None
Unknown
Laterality
Right origin
Left origin

Unspecified/Unk
Vital Status
Alive
Dead

0.12

(oo.o%)

(oo.o%)

o (.0%)
0.65

74 (14.1%)
17 (14.4%)

282 (53.6%)
68 (57.6%)

170 (32.3%)
33 (28.0%)

*As determined by any type of test

’Includes reports explicitly stating positive result (n=90) and FISH-positive conflicting result (n=l)
:Includes reports stating negative result (n=328), reports stating borderline result (n=7), FISHnegative conflicting values (n=10), FISH-borderline conflicting values (n= 1), and value given but no
decision (n=4, study decision IHC-negative).
Includes reports showing no indication of HER-2 testing (n=167), test order only (n=29), or
conflicting IHC results (n=7).
Pearson chi-squared test for proportions.

!1

q[ Asymptotic significance (2-sided).
#Kruskal-Wallis nonparametric test for independent samples (asymptotic significance, 2-sided)
** Counties with population counts <30 (n=5; Litchfield, Tolland, Middlesex, New London,
Windham) collapsed into "Combined".
Positive status includes only reports explicitly stating positive. Negative includes report of either

"

negative or borderline, unknown includes report of unknown, test ordered only, test not done.
::lncludes report of "test not done" (n=22).
Includes report of"test not done" (n=20).

Table 9. Distribution of HER-2 Status* by Demographic Characteristics of
Breast Cancer Patients (n=644), Connecticut Tumor
Registry, 2000-2003
P-value
Negative:
Positive"f
Unknown

Black/African-American

(n=91

County
composition#,**
Percent B/AA < CT
Percent B/AA > CT
County income’, **
45115
48834
50646
50756
56273
59044
59175
65249

County income,S, **
Median income < CT
Median income > CT

(n=350)

(n=203)
0.18

6 (13.3%)
85 (14.2%)

30 (66.7%)
320 (53.4%)

9 (20.0%)
194 (32.4%)

2 (66.7%)
21 (10.9%)
3 (13.6%)
28 (13.1%)
0 (.0%)

(33.3%)

0 (.0%)
79 (41.1%)
2 (9.1%)
61 (28.6%)
3 (75.0%)

<0.01

92 (47.9%)
17 (77.3%)
124 (58.2%)

1(33.3%)
0 (.0%)
36 (18.6%)

(25.0%)
(33.3%)
10 (76.9%)
104 (53.6%)

54 (12.6%)
37 (17.3%)

234 (54.4%)
116 (54.2%)

1(33.3%)
3 (23.1%)
54 (27.8%)

0.20

65

142 (33.0%)
61 (28.5%)

’*/s determined by any type of test.
Includes reports explicitly stating positive result (n=90) and FISH-positive conflicting result (n=l)
Includes reports stating negative result (n=328), reports stating borderline result (n=7), FISHnegative conflicting values (n= 10), FISH-borderline conflicting values (n= 1), and value given but
no decision (n=4, study decision IHC-negative).
Includes reports showing no indication of HER-2 testing (n=167), test order only (n=29), or
conflicting IHC results (n=7).
Pearson chi-squared test for proportions.
[ Asymp.Sig (2-sided).
# County % B/AA relative to CT proportion as a whole (9.1%).
** Based on 2000 U.S. Census data.
Median household income in U.S. dollars (1999).
Median household income in U.S. dollars (1999) relative to that of CT.

]

Table 10. Correlation of Patient Characteristics* with HER-2 Testing
Spearman correlation (r)
Diagnosis age
Medicare eligible
Year of diagnosis
Tumor size (mm)
Number positive nodes
Nodal status
County size
Grade

-0.071
-0.040
0.037

0.096"

County composition
Cgunty composition binary

0.045
0.037
0.064
0.024
-0.037
-0.051

ER status
PR status
Histology
Stage

0.043
0.030

_.County median income
County median income binary
ER testing
PR lesting
Grade testing

Lymph node testing

0.081"
0.049

0.505"*
0.519"*
0.150"*
0.188"*

* Unknown values set to missing.
By any type of test. Cases considered tested (n=477) if report shows any indication of HER-2
test regardless of outcome, cases considered unknown (n= 167) if report shows no indication of
test.
Correlation is significant at the 0.05 level (2-tailed).
Correlation is significant at the 0.01 level (2-tailed).

Table 11. Correlation of Patient Characteristics* with HER-2
Spearman correlation (r)
Diagnosis age

0.020

Medicare eligible
Year of diagnosis

-0.11

-0.0220
66

Status

Tumor size (mm)

0.013
0.101
0.086
0.075
0.080
-0.049
0.029
-0.095

Number positive nodes
Nodal status
County size
Grade

County composition
County composition binary
ER status
PR status
Histology

Stage

0.049
0.053
0.064

County median income
County median income binary

*

Unknown values set to missing.
As determined by any type of test. Positive status (n=91) includes reports called positive (n=90)
and FISH-positive conflicts (n-l). Negative status (n=350) includes all reports called negative
(n=328), FISH-negative conflicts (n=10), reports called borderline (n=7), FISH-borderline conflicts
(n=l), value given but no decision (n=4; all IHC-negative study decisions). Unknown values
(n-203) include IHC conflicts (n=7), test ordered only (n=29), and unknown (n=167). Unknown
values set to missing.
Correlation is significant at the 0.05 level (2-tailed).

Table 12. Unadjusted Odds Ratios and 95% Confidence Intervals for
Characteristics Tested for Association with HER-2 Testing* among Black/AfricanAmerican Breast Cancer Patients (n=644), Connecticut Tumor Registry, 2000..2003: Results of Univariate Logistic Regression Analyses
Characteristic

OR

95 %CI

17.30
1.00

0.31, 29.03
Referent

19.50
1.00

11.45, 33.20
Referent

0.60
1.00
0.99

0.37, 0.98
Referent
0.98, 1.00

0.07

1.00
0.74
0.91
1.18
1.00
1.03

Referent
0.44, 1.22
0.55, 1.51
0.69, 2.00
0.99,1.02
0.96, 1.11

0.23
0.72
0.55
O.5O
0.41

1.21
1.00
1.00

0.78, 1.87

0.40

1.00, 1.00

0.40

1.00
1.13

Referent
0.72, 1.79

0.59

P- value
<0.001

ER testing

Yes
Unknown
PR testing

YesUnknown

<0.001

PR status
Positive
Negative

Diagnosis age
Year of diagnosis
2000
2001
2002
2003

Tumor size
Number positive nodes
Nodal status
Positive
Negative
County population size
County of residence
Hartford
Fairfield

0.04
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New Haven

0.65
1.49
1.07
0.001

0.42, 0.99
0.65, 3.41
0.80, 1.43
0.00, 25.91

0.05
0.34
0.65
0.18

0.60
1.00

0.27, 1.31
Referent

0.20

0.61
1.00

0.36, 1.02
Referent

0.06

1.00
2.18
1.06

Referent
0.83, 5.73
0.53, 2.09

0.11
0.88

1.00
1.37
0.63
1.00

Referent
0.92, 2.05
0.29, 1.36
1.00, 1.00

0.12
0.24
0.12

Median income _> CT
Median income < CT
Lymph nodes tested

1.27
1.00

0.87, 1.87
Referent

0.22

Yes
Not done/unknown

2.65
1.00

1.76, 3.98
Referent

<0.001

2.63
1.00

1.58, 4.39
Referent

<0.001

0.82
1.00

0.57, 1.19
Referent

0.31

Combied][
Grade

County composition, #
County composition,**
Percent B/AA > CT
Percent B/AA < CT
ER status
Positive

Negative
Histologic type
Ductal
Lobular
Mixed
SEER stage
Local

Regional
Distant

County income,
County income,

Grade tested

Yes
Unknown
Medicare eligible
< 65 yrs
>_ 65 yrs

Abbreviations: OR, odds ratio; CI, confidence interval
* By any type of test.
Includes reports showing a test result or a test order.
Includes report of "test not done" (n=22).
Includes report of"test not done" (n=20).
Counties with population counts <30 (n=5" Litchfield, Tolland, New London, Middlesex,
Windham) collapsed into "Combined".
Based on 2000 U.S. Census data.

"

# Percent B/AA population.
** County % B/AA relative to CT proportion as a whole (9.1%).
Median household income in U.S. dollars (1999).
Median household income in U.S. dollars (1999) relative to that of CT.

’
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Table 13. Unadjusted Odds Ratios and 95% Confidence Intervals for
Characteristics Tested for Association with HER-2 status* of Black/AfricanAmerican Breast Cancer Patients (n=441), Connecticut Tumor Registry, 20002003" Results of Univariate Logistic Regression Analyses
OR

95%CI

P- value

1.00
1.19
0.69
0.50

Referent
0.64, 2.21
0.37,1.32
0.25, 1.02

0.58
0.27
0.06

0.74
1.00
1.00
0.99
1.02

0.45, 1.19
Referent
0.99, 1.02
0.98, 1.01
0.96, 1.09

0.21

1.54
1.00
1.00

0.92, 2.58
Referent
1.00, 1.00

0.10

1.00
1.53
1.01
0.89
1.34
0.14

Referent
0.88, 2.68
0.54, 1.89
0.34, 2.33
0.92, 1.95
0.00, 14285

1.00
1.33

Referent
0.54, 3.29

0.63
1.00

0.39, 1.01
Referent

Year of diagnosis"
2000
2001
2002
2003

PR status
Positive
Negative
Diagnosis age
Tumor size
Number positive nodes
Nodal status
Positive

Negative
County population size
County of residence
Hartford
Fairfield

New Haven

Combined
Grade

County composition
County composition,]]
Percent B/AA > CT
Percent B/AA < CT
ER status
Positive

Negative
Histologic type
Ductal
Lobular
Mixed
SEER stage
Local

Regional
Distant

County income,
County income,#
Median income _> CT
Median income < CT
Medicare eligible
_> 65 yrs

< 65 yrs

0.73
0.55
0.49

0.50

0.13
0.97
0.8|

0.13
0.74

0.54
0.05

1.00 Referent
0.69 0.25, 1.85
0.59 0.22, 1.58

0.46
0.29

1.00
1.29
1.26
1.00

Referent
0.79, 2.10
0.39, 3.99
1.00, 1.00

0.31
0.70
0.16

1.38
1.00

0.86, 2.22
Referent

0.18

0.90
1.00

0.54, 1.49
Referent

0.67

Abbreviations: OR, odds ratio; CI, confidence interval.
*As determined by any type of test. Unknown values (n=203) include IHC conflicts (n=7), test
ordered only (n=29), and unknown (n=167). Positive status (n=91) includes reports called positive
(n=90) and FISH-positive conflicts (n=l). Negative status (n=350) includes all reports called
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negative (n=328), FISH-negative conflicts (n= 10), reports called borderline (n=7), FISH-borderline
conflicts (n=l), value given but no decision (n=4;all IHC-negative study decisions).
f Continuous variable coded in ascending order.
Counties with population counts <30 (n=5; Litchfield, Tolland, New London, Middlesex,
Windham) collapsed into "Combined".
Based on 2000 U.S. Census data.
County % B/AA relative to CT proportion as a whole (9.1%).
Median household income in U.S. dollars (1999).
# Median household income in U.S. dollars (1999) relative to that of CT.

[I

Table 14. Multivariate Analysis*,? of the Relation Between Patient Characteristics
and HER-2 Testing among Black/African-American Breast Cancer Patients
(n=425),:[: Connecticut Tumor Registry, 2000-2003
Variable

Model (goodness of fit
Diagnosis age
Year of diagnosis
200o
2001
2002
2003

[I

I

OR

95% CI

P-value

1.01

0.99, 1.03

0.57

1.00
0.86
1.76
1.25

Referent
3.90, 1.89
0.76, 4.04
0.55, 2.84

0.70
0.19
0.60

1.00
0.79

Referent
0.43, 1.46

0.46

1.00
22.46
0.85
4.09

Referent
1.68, 300.32
0.45, 1.59
0.52, 32.14

0.02
0.60
0.18

0.17
1.00

0.02, 1.93
Referent

0.15

I. 11

0.59, 2.06
Referent
0.98, 1.02

0.75

1.00
1.00

1.53
1.00

0.47, 4.97
Referent

0.48

0.932)

ER status
Negative
Positive
County of residence
Hartford
Fairfield

New Haven
Combined#
County income* *, ?"f
Median income >CT
Median income <CT
Nodal Status
Positive
Negative
Tumor size
Grade tested

I

Yes
Unknown

0.96

Abbreviations: OR, odds ratio; CI, confidence interval.
* Results for model using ER tested and ER status. When PR variables were substituted for the
analogous ER variables, significant covariates included Fairfield County (OR-20.68, P=0.02).
The variables ER test done and lymph nodes examined were constant for all selected cases;
removed from analysis.
219 cases excluded from analysis.
Hosmer and Lemeshow goodness-of-fit statistic.
Continuous measure.

1]
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Includes only reports explicitly stating positive or negative status.
Counties with population counts <30 (n-5; Litchfield, Tolland, New London, Middlesex,
Windham) collapsed into "Combined".
** County median household income in U.S. dollars (1999) relative to that for CT.
Based on 2000 U.S. Census data.
Excludes patients with unknown nodal status (n-133).

’

Table 15. Multivariate Analysis* of the Relation between Patient Characteristics
and HER-2 status? among Black/African-American Breast Cancer Patients
(n=303),$ Connecticut Tumor Registry, 2000-2003
Variable
Model (goodness of fit

agel]

Diagnosis
Year of diagnosis
2000
2001
2002
2003

OR

95% CI

P-value

1.01

0.99, 1.03

0.44

1.00
1.71
1.00
0.35
1.01

Referent
0.78, 3.74
0.46, 2.18
0.13, 0.97
0.57, 1.78

1.84
1.00

0.98, 3.43
Referent

0.73
1.00
0.99

0.38, 1.39
Referent
0.97, 1.01

1.00
0.48
0.74

Referent
0.10, 2.25
0.23, 2.37

0.35
0.62

1.00
1.73
1.37
0.99

Referent
0.83, 3.58
0.64, 2.96
0.32, 3.13

0.14
0.42
0.99

0.885)

]

Grade
Nodal Statusq[
Positive

Negative

0.18
1.00
0.04
0.99
0.06
0.06

ER status#
Positive

Negative

Tumor size

1[

Histologic type
Ductal and related
Lobular
Mixed ductal and lobular
County of residence
Hartford
Fairfield

New Haven
Combined**

0.34
0.30

Abbreviations: OR, odds ratio; CI, confidence interval.
* Results for model using ER status. When PR status was substituted, significant covariates included
diagnosis year 2003 (OR= 0.35, P=0.04).
As determined by any type of test.
341 cases excluded from analysis.
Hosmer and Lemeshow goodness-of-fit statistic.
Continuous measure.
Excludes patients with unknown nodal status.
# Includes only reports explicitly stating positive or negative status.
** Counties with population counts <30 (n=5; Litchfield, Tolland, New London, Middlesex,
Windham) collapsed into "Combined".
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